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ABSTRACT  
Background: The cornerstone of malaria case management is prompt and effective 
treatment. In Kenya, the National Guideline for the Diagnosis, Treatment and Prevention of 
Malaria has changed over the past 12 years and in 2004 Artemisinin Combination Therapy 
(ACT) was introduced as first line treatment for uncomplicated malaria. Successful 
implementation of this policy depends on changing prescribing patterns of health workers and 
this requires regular assessment of progress made and application of lessons learnt to inform 
future policy and practice.  
 
Aim: The aim of this study was to assess the prescribing practices and availability of anti-
malarial drugs to children under five years of age in primary health care facilities in Bondo 
district.  
 
Study design: This was a facility-based cross-sectional study using an adapted WHO 
methodology and tools.  
 
Study population and sample: A sample of 20 primary health care facilities were selected 
from Bondo district using cluster sampling and 30 care givers with their children who were 
under five were selected from each of these facilities using simple random sampling. 
 
Data collection: Three forms were used to collect data: a prescription indicator form, a 
prescribing encounter and patient care form, and a health facility indicator form. Data was 
collected using two trained data collectors familiar with the local language and setting and 
then analyzed using SPSS.  
 
Results: Six hundred children and their care givers were interviewed in the 20 primary health 
care facilities. Of the children who were diagnosed with uncomplicated malaria and 
participated in the study 63.5% were females while 36.5% were males. Artemisinin 
lumefantrine (AL) was prescribed and dispensed to 99.2% while quinine was prescribed to 
0.8%. Malaria laboratory confirmatory tests were carried out in 100% of children. 
Furthermore, 44.5% were given the first dose of AL at the facility with swallowing of the 
first dose observed at the facility in 40.5% of the children. Concerning caregivers, 81.7% 
reported receiving explanations about the importance of completing malaria treatment 
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regimen and 98.3% knew that AL is the drug choice for treatment of malaria, however, 
disappointingly 96.7% of the care givers were not told what to do if the child vomits after 
taking AL. All primary health care facilities had AL and other key anti-malarial drugs in 
stock and 95% of the primary health care facilities had wall charts with the treatment regimen 
for the prescribing of AL.  
 
Conclusion: Although more than 90% of the children in the primary health care facilities in 
Bondo district were prescribed and received AL for treatment of malaria, the quality of AL 
case management at the point of care was not optimal compared to the National Guidelines 
for the Diagnosis, Treatment and Prevention of Malaria requirements. Improved training of 
health workers on the importance of patient supportive care for caregivers of children under 
five should be introduced to achieve a malaria free zone in Kenya by 2017. Monitoring and 
evaluation of these recommendations are essential so that adjustments can be made towards 
improving patients’ support. 
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CHAPTER ONE: INTRODUCTION 
1.1 Background 
Malaria is one of the most important public health problems worldwide, particularly in children 
under five years of age. According to Bryce et al (2005), out of the 10.6 million annual deaths 
among children under five years old globally, 8 percent are attributed to malaria. Despite this, 
malaria control and eradication was neglected for decades and has only reclaimed global health 
attention since the initiation of programmes like ‘Roll Back Malaria’ (RBM),  launched in 1998  
by three United Nations agencies and the World Bank (Anonymous, 2007; Feachem  and Sabot, 
2008; Tanner  and de Savigny, 2008;  and RBM WHO, 2008). RBM (2008) reported that malaria 
accounts for one in five of all childhood deaths in Africa and estimated that out of the 500,000 
children that develop cerebral malaria annually, 10-20% of these children die and 7% are left 
with permanent disability. Prompt use of an effective anti-malarial drug is essential for 
controlling malaria. The World Health Organization (WHO) recommends an artemisinin-based 
combination therapy (ACT) as the first-line treatment of uncomplicated malaria in children under 
five. 
  
The disease remains a major public health problem in Kenya, accounting for 30% of outpatient 
consultations, 19% of inpatient admissions and up to 5% of patient deaths (DOMC, 2009). 
According to the Kenya Demographic Health Survey 2008-2009 the under five child mortality 
rate is at 74 deaths/1000 live births. The report further states that in the two weeks preceding the 
survey, 24% of the children under five had fever and out of this only 23% took anti-malarial 
drugs. In addition to this, 11% took anti-malarials on the same or next day (KNBS, 2010). 
Furthermore, 8% of the children under five with fever took ACT, 3% took Fansidar. Only 4% of 
the children took ACT on the same or next day after onset of fever and 2% took Fansidar on the 
same or next day. Disappointingly, 8% of the children were still being given amodiaquine 
(KNBS, 2010). These figures are a clear indication that more needs to be done with regards to 
malaria treatment for children under five with respect to ACT policy adherence, since the failed 
monotherapies that were done with away are still being prescribed in Kenya.  
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The Kenya Malaria Indicator Survey carried out in 2010, revealed that the lake side endemic 
zone had the highest percentage of the children who had fever two weeks prior to the survey, at 
41% compared to the coastal endemic region with 30%. It further states that treatment seeking 
behavior among children under five is lowest in lake side endemic zone at 50% compared to the 
coastal endemic zone which is highest at 75 % (DOMC, 2011). This could be due a larger 
number of non governmental organizations present in the coastal region compared to the lake 
side region.  In addition, only 24% of the children under five from the lake endemic zone took 
ACT. 
 
The Division of Malaria Control Programme (DOMC) in conjunction with Ministry of Public 
Health & Sanitation (MPHS) employs four strategic approaches to control malaria across the 
country. They include firstly, ensuring the use of insecticide treated nets (ITNs) and other vector 
control  measures by the at-risk communities; secondly, providing malaria prevention and 
treatment to pregnant women; thirdly, improving malaria epidemic preparedness and response; 
and lastly, case management which  guarantees  people access to quick and effective treatment 
(MOH, 2004). This fourth strategy, case management, is of most relevance to this study as its 
cornerstone lies in the early diagnosis (malaria laboratory tests or rapid diagnostic test) and 
prompt treatment with a recommended antimalarial drug as stipulated in the National Guidelines 
for Diagnosis, Treatment and Prevention of malaria (DOMC, 2010). 
  
The current policy treatment in Kenya recommends artemesinin-based combination therapy 
(ACT) as a first line treatment of uncomplicated malaria. According to the National Guidelines 
for the Diagnosis, Treatment and Prevention of Malaria in Kenya (DOMC, 2010), only ACTs 
that are co-formulated should be used for uncomplicated malaria. It further says that the ACTs 
should include at least three days of treatment with an artemisinin derivative. Paediatric 
formulations should be used for infants and children to ensure the correct dosing (Appendix 1). 
In addition to this, the care givers of the children under five, need counseling and follow up as 
part of the treatment. The health care provider needs to observe swallowing of first dose of the 
treatment, teach the care givers how to prepare dispersible tablet prior to administration, educate 
the care giver on what to do when vomiting occurs after administration of  the drug, explain 
dosing schedule and confirm that the care givers understands by using probing questions, 
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emphasize on dose completion even when the child feels better after starting the treatment 
regimen and advise on return to the nearest health care facility in case the patient’s condition 
deteriorates or symptoms do not resolve after completion of treatment, that is, three days. Second 
to these, the health care providers need to prescribe, preferably, paracetamol as an anti-pyretic to 
manage fever. The care giver also needs to be educated on conservative management of fever 
such as tepid sponging, exposure and fanning. The care giver needs to be encouraged to give 
plenty of fluids to the child and continue breast feeding where applicable (DOMC, 2010). 
 
This study was motivated on the basis that case management rests on prompt and effective 
treatment of malaria, and is one of the strategies to lower the child mortality and morbidity rate 
caused by malaria in Kenya.  
 
1.2 Problem Statement 
Artemisinin-based combination therapies (ACTs) were introduced as first line treatment for 
uncomplicated malaria in Kenya in September 2006 with the aim of addressing the problem of 
failing monotherapies (amodiaquine and choloroquine) and reducing the enormous burden of 
malaria across the country (Snow et al, 2005; WHO, 2006). However, the 2007 Malaria Indicator 
Survey did not show much improvement in case management practices, that is, diagnosis and 
prompt treatment of malaria, with the survey finding that only 4.7% of children under-five 
received ACT treatment within 24 hours (PMI, 2009). This is far short of the Abuja declaration 
target of 60% (MOH, 2003). The President’s Malaria Initiative (PMI) programme in Kenya 
(2009) asserted that the Ministry of Health, Division of Malaria Control programme (DOMC), 
diagnosis and treatment of malaria was an area of concern, as prompt and accurate diagnosis of 
malaria is key to effective disease management, and reducing the unnecessary use of anti-
malarial drugs. This study sought to identify the prescribing practices in primary health care 
facilities among the children under five in Bondo district and compare them to the national 
treatment guidelines. In addition, the study also assessed the availability of anti-malarial drugs at 
these facilities. 
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1.3 Study setting 
The study was conducted in Bondo district, Siaya County in Kenya. The district covers a total of 
1,972km
2. 
It borders, Kisumu County to the East and Homa Bay and Suba across the Winam 
Gulf to the Southeast and to the West is Uganda. The district has a modified equatorial climate. 
Predominantly, it has warm, dry and humid climate with mean annual rainfall ranging between 
800-1600 mm. Long rains occurs between March and May and short rains occurs between 
October and November. It is a lake side malaria endemic area where transmission occurs 
throughout the year, though it is highest during two rainy seasons annually. The malaria 
morbidity rate is 34% (UNPEI, 2007). Bondo district is a rural setting with a population of 
approximately 238 780 with 47% of the population 14 years old or less, and 58% are 19 years or 
less.  
 
There are 3 divisions in Bondo district namely Maranda, Nyawita and Usigu each headed by a 
district officer. It has a total of nineteen locations and forty-nine sub-locations.  
 
According to the Ministry of Public Health and Sanitation, there are 29 primary health care 
facilities in the district, 27 dispensaries and 2 health centres (MOH, 2010). However, during data 
collection, which was carried out during the rainy season, two of the dispensaries had been 
elevated to health centres. The district has one referral hospital, Bondo district hospital. The 
majority of the dispensaries and health centres are headed by registered nurses while others are 
headed by clinical officers. The registered nurses have a diploma in nursing while the clinical 
officers have a diploma in medicine. Each is responsible for prescribing drugs to patients. The 
other staffs include enrolled nurses (certificate nurses), pharmacy technicians, public health 
officers, nurse aids and subordinate staff. All the health facilities operate during weekdays from 
8am to 6pm and are closed at weekends (Saturday and Sunday). 
 
The primary health care facilities included in the study area were government facilities and 
mission hospitals. Some of the health care facilities are in remote areas and are only accessible 
by use of motor bikes, especially during rainy season when this study was conducted. In 
addition, some are on the island making entry weather dependant as experienced during data 
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collection. Furthermore since the only mode of transport is a motor boat, the tides have to be low 
for accessibility. 
 
All these primary health care facilities have laboratories that perform malaria blood diagnostic 
tests before drugs are prescribed and dispensed. The patients pay a fee of Kshs. 30 an equivalent 
of $0.35 for this malaria test. This payment is demanded by the facility health committee for the 
steady supply and procurement of laboratory reagents. This is because supply from government 
is never sufficient and for the health care facilities to maintain laboratory services the patients 
have to co-share the cost hence the demand for payment of $0.35 The patients are neither 
required to pay for consultations or for the anti-malarial drugs.  
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Figure 1: A map of  Bondo district ( Study area ) 
 
 
Source. http://www.flickr.com/photos/albertkenyaniinima/6671945119/sizes/o/in/photostream/ 
NOTE: The red line borders are the existing ward boundaries    
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CHAPTER TWO: LITERATURE REVIEW 
2.1 Introduction 
Appropriate caew management of malaria was identified as one of the four strategic approaches 
to control malaria in Kenya (MOH, 2004). This involves those with malaria, including children 
under five years of age, receiving prompt and effective treatment with anti-malarial drugs in 
accordance with the current National Guidelines for Diagnosis, Treatment and Prevention of 
malaria in Kenya (DOMC, 2010).  A number of different factors have been shown to influence 
adherence to malaria guidelines, particularly when significant changes have been made to the 
policy such as malaria testing and recommended drug regimens. These include prescribing 
practices of health workers, availability of drugs at health facilities and the knowledge of patients 
and caregivers of malaria treatment. 
 
2.2 Prescribing patterns of anti-malarial drugs among under fives 
Successful implementation of any new anti-malarial policy depends on changing prescribing 
patterns of health workers (Ucakacon et al, 2011). According to Wasuna et al (2008), failure of 
health workers to prescribe drugs stipulated in a drug policy may be due to issues such as the 
high cost of drugs, contradicting training messages in the recommended guidelines, insufficient 
drug supply, availability of non-recommended drugs causing prescription confusion and lack of 
follow-up supervision. Ucakacon et al (2011), suggest that performance of health workers could 
be evaluated by assessing their prescribing habits and says these prescribing habits may be 
influenced by a number of factors including lack of training, shortage of drugs, financial 
influences, patient load, lack of materials and prescribing attitudes. All of which are challenges 
in a typical health centre setting in Africa. 
 
Asia portrays specific challenges for ACT use. Low coverage, poor targeting and monotherapy 
use in the private sector are cited as some of the challenges that influence prescribing patterns of 
ACT (Yeng et al, 2008). A review by Whitty et al (2008), comments that in Eastern Asia 
tolerance of malaria parasites to artemesinins are already a concern. In addition across Asia and 
Africa, there is substantial evidence that at most of the formal healthcare settings where ACTs 
are provided, a large proportion of children and adults presenting with fever are prescribed anti-
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malarials, even though they may not have malaria parasites in their blood (Hamer et al, 2007, 
Reyburn et al, 2007). However, in South East Asia, the successful use of diagnostic services, 
both microscopy and rapid diagnostic tests (RDTs), provides useful models for other settings like 
Africa (Kolaczinski, 2007; Ratcliff, 2007). 
 
According to DOMC (2010), malaria is either classified as uncomplicated or severe 
(complicated) based on the clinical presentation. It further states that uncomplicated malaria is 
defined as symptomatic infection with malaria parasetemia without signs of severity and/or 
evidence of vital organ dysfuntion while severe malaria/complicated malaria  is defined as acute 
malaria with signs of severity and /or evidence of vital organ dysfunction.  
 
Irrational prescribing of anti-malarial drugs is abundantly evident in most African countries. This 
is cited by Jowett and Miler (2008), and Oshikoya et al (2006). Kamuhabwa and Ramji (2011) 
conducted a study in Tanzania to determine the prescribing and dispensing practices for 
pediatrics and found that 65% were prescribed AL while 35.5% were prescribed quinine. 
However, the 35.5% that were prescribed for quinine did not present with symptoms of severe 
malaria even though the national guidelines for the diagnosis and prevention of malaria indicates 
that quinine should only be prescribed as first line treatment for complicated/sever malaria. This 
is a worrying trend since the treatment guideline recommends AL as first line for treatment of 
uncomplicated malaria. In addition, the prescribers had moderate knowledge with regards to anti-
malarial drug use and supportive care. Whitty et al (2002), asserts that lack of knowledge of anti-
malarial use in pediatrics is a serious problem especially in high endemic areas where anti-
malarials are repeatedly given to treat frequent fevers in the absence of malaria. This increases 
resistance and frequency of adverse drug reactions. 
  
A study conducted in rural districts in Uganda, one year after implementation of artemether-
lumefantrine (AL), an ACT, as a first line treatment of uncomplicated malaria, revealed that 60% 
of patients were prescribed AL of which 95% of these patients had correct dosage prescribed; 
14% chloroquine and sulphadoxine pyrimethamine (CQ+SP); 4% quinine; 3% various other anti-
malarials; and 16% had no anti-malarials prescribed to them at all. In addition, the health 
workers were more likely to prescribe AL weight specific packs if they were in stock, but also if 
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non-recommended chloroquine was absent (Ucakacon et al, 2011). This study highlights the 
importance of having steady supply of AL weight specific packs in rural health care facilities to 
facilitate health workers adherence to the national treatment guidelines. 
 
Another review carried out to evaluate treatment practices for uncomplicated malaria after the 
policy change from SP to AL in four districts in Zambia showed that among children weighing 
10 kilograms or more, SP was prescribed to 68% of children, whereas the recommended AL was 
prescribed for only 11%. Among children weighing less than 10 kilograms seen at facilities 
where AL was available, AL was prescribed for 22% of children and SP for 54% (Njuguna and 
Qader, 2007). This study emphasized that when a new drug policy is introduced, the transition 
period is crucial and must be managed effectively to ensure positive results. This calls for 
extensive education to sensitize prescribers and the general public.  
 
The Kenya Malaria Indicator Survey conducted in 2010, showed that in the lake endemic zone 
41% had fever two weeks prior to the survey and out of these 50% sought treatment from the 
health care facilities. Of the children who sought treatment in the health care facilities (the 50%), 
40% took anti-malarials and 24% took ACT, however only 10.9% of these children (who sought 
treatment from the health care facility above) under five had blood taken from either their fingers 
or heel for diagnostic malaria laboratory test (DOMC, 2011). It further says that in the same lake 
endemic zone the under five that took ACT same or next day were, 15.5%. Those who took other 
anti-malarials included SP/F 1.2%, CQ 0%, AQ2.7%, Q 2.6%, other anti-malarials, 3.2% 
(DOMC, 2011). The above figures illustrate that ACT use among under five is still low in the 
lake endemic zone although there is an improvement from the 2008-2009 health indicator survey 
where 8% of the children under five with fever received ACT and 4% received it same or next 
day (KNBS,2010). Another point to note from these figures, the percentage of children that had 
malaria laboratory tests done is still low since the National Guidelines for Diagnosis, Treatment 
and Prevention of malaria strongly recommends that all patients regardless of age should have 
their blood tested for malaria before ACT is prescribed. This can lead to unnecessary 
prescription of ACT leading to artemesins parasite resistance.  
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Therefore, more effort needs to put by DOMC  to ensure that treatment policy is  adhered to by 
the health care providers in all the health care  institutions and more so the endemic areas where 
the figures of ACT uptake is still way below the 60% mark of the Abuja declaration especially 
among under five children. More so the prescription of failing monotherapies that are not to be 
prescribed (as per the National Guidelines for the Diagnosis, Treatment and Prevention of 
malaria in Kenya) still appears to be given to these children is a more worrying trend that needs 
to be addressed.  
 
Earlier studies done in Kenya by Zurovac et al (2008), Skarbinsnki et al (2009) and DOMC 
(2009) revealed that, overall AL use was low in both under five and above five to 14 years, with 
current practice of prescribing non-recommended amodiaquine (AQ), SP and their combinations; 
secondly a substantial proportion of young children were tested for malaria; and lastly, 
prescriptions of AL largely followed test results and recommendations. However they found that 
most test negative patients were still treated for malaria mainly with alternative and non-
recommended treatment. 
  
More recent studies in Kenya seem to indicate some improvements in adherence to the new 
malaria policy guidelines. A study conducted three years after AL implementation in Kenya 
revealed that for children under five that presented with fever 63.6% were treated with the 
recommended AL, 9% were treated with non-recommended quinine or combination of AL and 
quinine, 2% received ineffective AQ or SP monotherapies and 25.4% were not treated for 
malaria. In addition, among test positive under five children, 74.7% of the children were treated 
with AL, 18.7% with AL+QN and 5.5% with quinine alone. However, among test negative 
children, AL was prescribed for 40.4% of these children, 9.1% were treated with AL+QN or 
quinine alone and 7.1% were treated with either AQ or SP monotherapies. At least one anti-
malarial drug was prescribed for 56.6% of the test negative (Juma and Zurovac, 2011). All 
patients in this study were tested for malaria. 
 
A survey done in Bondo district and other four endemic areas in Kenya on barriers to promote 
effective malaria treatment among the poorest populations revealed that low levels of ACT 
uptake could be attributed to poor prescribing practices, as well as other factors such as frequent 
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stock outs in public health care facilities, limited availability outside the public sector and high 
costs (Chuma et al, 2010). The study emphasized the importance of addressing all these issues to 
improve adherence to the malaria treatment guidelines.  
 
2.3 Availability of anti-malarial drugs in health care facilities 
National malaria management strategy is established upon accessibility to efficient and 
inexpensive anti-malarial drugs (Alexandre et al, 2010). Availability of the recommended anti-
malarial drugs at all primary health care facilities is crucial for the smooth implementation of any 
anti-malarial drug policy, however a number of studies have found that stock-outs are frequent 
occurrences in health facilities in a number of African countries. 
 
The aim of malaria management policy is to provide therapeutic guidelines to health workers and 
efficacious and affordable drugs to health facilities for patients to buy. This policy must be based 
on proper laboratory diagnosis and treatment of malarial episodes. Given the rapid evolution of 
parasite resistance to chloroquine and sulfadoxine-pyrimethamine (SP), several countries have 
modified their national policy and adopted the artemisinin derivative combined treatments 
(ACT’s) as recommended by (WHO, 2006).  
 
Lack of first line anti-malarial treatment in Sub Saharan Africa has been mentioned extensively 
as the main problem in the health care systems (Hetzel et al, 2008).This is reported as 
problematic in several other studies (Kangwana et al 2009; Zurovac et al, 2008; Chuma et 
al,2009;  Zurovac et al, 2008). According to Chuma et al (2009), a survey carried out in two 
districts in Kenyan coast indicated that drug shortages occurred during the peak illness and 
towards the end of the drug supply period. The author asserts that such factors lead to poor 
adherence to treatment policy. 
 
A study undertaken in Uganda to review malaria case management under AL showed that  on the 
survey day, any tablet packs of AL were in stock at 87% of facilities, the availability ranging 
from 39% for 18 tablet packs to 83% for 6 tablet packs. All four weight-specific AL packs were 
available at only 34% of the facilities. Other anti-malarial drugs recommended for treatment of 
uncomplicated malaria such as quinine, artesunate and amodiaquine were respectively in stock at 
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only 30%, 4%, and 2% of facilities. Disturbingly, non-recommended anti-malarials were widely 
available, CQ at 77% and SP at 88% of facilities. The figures above point to the likelihood of 
stock outs of the ACTs or other anti-malarials recommended in the policy influencing the 
prescribing habits of health workers and resulting in use of the non recommended antimalarials  
and hence not adhering to the national treatment guideline (Zurovac et al, 2008). 
 
Lack of ACTs in the rural health care facilities in Kenya is attributed to several factors including 
high cost of treatment, long distance to the health care facilities, poor infrastructure, opening 
hours that are not friendly to clients and staff shortages just to mention a few (Chuma et al, 
2010). A survey done in four districts in Kenya showed that a third of the individuals that sought 
treatment did not get drugs from the hospital pharmacy due to anti-malarials being out of stock. 
This stock outs were majorly experienced during the wet seasons when malaria infections are 
high (Chuma et al, 2010). These drugs stock outs may not only create mistrust between 
community and health workers but it also makes treatment unaffordable since patients are forced 
to seek alternative treatment in either private hospitals or local pharmacies that are equally 
costly. 
 
One of the factors that influence availability of anti-malarial drugs is the poor road network that 
becomes inaccessible during wet seasons. This hinders not only the patients in getting the anti-
malarial treatment but also the health care providers who might not report to work due to remote 
and inaccessibility of the health care facility to provide anti-malarial treatment needed (Noor et 
al, 2005). Several authors report in their findings that, the opening and closing hours of rural 
health care facilities remains a major challenge to accessibility of anti-malarials (O’Meara et al, 
2009; Gething et al, 2004 and Chuma et al 2010). This is because most of the primary health 
care facilities are closed during the weekends, that is, Saturday and Sunday, The patients are 
therefore forced to wait until Monday when the drugs will be available as the health facility 
remains closed. This in turn becomes a barrier to effective malaria treatment. 
 
A cross-sectional survey carried out in 164 government health care facilities (115 dispensaries, 
30 health centers, and 19 hospitals) in high endemic areas across Kenya to assess availability of 
AL two years after its implementation, revealed that approximately a quarter (25.6%) of the 
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surveyed facilities had none of the four AL weight-specific treatment packs in stock, with 
complete stock outs more common in dispensaries (30.4%) than in health centers (20.0%) and 
hospitals (5.3%). Furthermore, three quarters (75.0%) of the facilities were out of stock of at 
least one weight-specific AL pack. It was particularly worrying that packs for the youngest age 
group, the group most at risk of malaria mortality, were absent in nearly two-thirds (61.0%) of 
facilities (Kangwana et al, 2009).  
 
Chuma, Okungu and Molyneux (2010) asserted that drug availability was a key factor that 
influenced access to treatment. These researchers conducted a study in four rural districts in 
Kenya (Gucha, Kwale, Bondo and Makueni districts) and the results found that 30% of people 
who visited public health facilities did not get their drugs from the hospital pharmacy and were 
issued with a prescription to buy drugs elsewhere. Of these, only 32.8% individuals bought the 
prescribed drugs. In addition, among exit interview participants, 38.8% did not receive drugs 
from the facility because they were out of stock. Persistent shortages of anti-malarials in public 
healthcare facilities reportedly discouraged people from seeking effective treatment. Participants 
were vocal about chronic drug shortages in the public health facilities and the implications this 
had on affordability and treatment seeking behavior (Chuma, Okungu and Molyneux, 2010). 
 
Another survey in the above named four districts (Bondo included) in Kenya to evaluate why 
health workers do not prescribe ACT indicated that there was fear of stock-outs in all the districts 
that the studies were conducted. The report further says that the health workers stated that the 
supply of AL was inconsistent during the initial stages of policy implementation. Three districts, 
including Bondo, had experienced at least one month of AL stock-out during the three month 
period (December 2006 to February 2007). Virtually all health workers indicated that they were 
rationing the drug because they were not certain when the next supply would be available basing 
their experience on the previous stock-outs periods (Wasuna et al, 2008). 
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2.4 Care givers knowledge on treatment and patient care 
Caregiver’s knowledge in the management of malaria is crucial in reducing child mortality and 
morbidity caused by malaria. Caregivers need to know and understand that prompt treatment, 
correct dosage and completion of treatment is essential in treating malaria and limiting drug 
resistance. Studies in several sub-Saharan African countries have investigated this critical aspect 
of malaria treatment and care. 
 
A study undertaken in Sudan to assess prescribing habits of health workers revealed that the 
care-givers had poor knowledge of the anti-malarial treatment they had received. The researcher 
speculated as to whether the information on the prescribed drug was issued voluntarily or the 
care-giver was expected to ask questions regarding the dispensed anti-malarial (Mannan, Malik 
and Ali, 2009). Failure of the dispenser to convey the correct message regarding treatment to the 
care giver could result in compromised treatment. In addition, the study showed poor labeling 
practices in many health centers, including, lack of patients’ names, incomplete dosage schedules 
and sometimes incorrect dosages. This could have been due to lack of knowledge of appropriate 
labeling practices by the dispensers (Mannan, Malik and Ali, 2009). A similar study done in 
Uganda by Zurovac et al (2008), revealed that of the 669 patients 97% received explanations 
about how to take AL at home, 67% were advised to complete all doses, 47% were instructed to 
take the drug after a meal, 15% received the first AL dose while at the facility, 14% were 
observed while swallowing he first dose and 7% were advised what to do in case of vomiting..  
 
In Tanzania, a survey was done to assess knowledge of care givers on AL prescribed to their 
children under five. It was noted that 67% of parents/care givers had a moderate level of 
knowledge regarding the instructions given by prescribers on AL home use and 33% had low 
level of understanding of the instructions given for anti-malarial home use. The argument here is 
that if these parents (a large number) who have a low level of understanding instructions on drug 
home use then how will the drug be of benefit to the child to cure malaria that it is intended to? 
In addition to this, only 2% of parents could comprehend supportive care (which includes fever 
management, fluid and nutritional in take during treatment) while 69% had moderate 
understanding of supportive care and 30% had a low understanding on supportive care. These 
figures are of a great concern as it means that the care givers who ought to know the supportive 
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care that is outlined in most national treatment guidelines are not aware, and so the adherence to 
treatment guideline is in jeopardy. This trend could be an indication that the drug dispensers are 
not transmitting the messages that they ought to. In this study the researchers attributed this trend 
to heavy patient work load and so there is no time for the health care providers to pass the 
knowledge to care givers (Kamuhabwa and Ramji 2011). 
 
Wasuna et al (2010) conducted pre and post training surveys of health workers in Bondo district, 
the setting for this research, to assess four different dispensing  and counseling tasks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
performed by health workers to the caregivers of the children under five with malaria and treated 
with AL and dispensed in the facility. The four dispensing and counseling tasks evaluated 
included; firstly, weight measured, secondly, initial dose administered in the health facility, 
thirdly, explanation on dosage to take at home and emphasis on completion of   full course, 
fourthly, advice on vomiting. They found the following results from the pre and post training 
surveys: those to whom their weights were taken (74.2% and 79.0% respectively), those given 
first dose in the health facility (21.6% and 33.6% respectively), those to whom dosage to take at 
home was explained (98.5% and 99.1% respectively), finally those given advice on vomiting 
(3.3% and 8.0% respectively). During both pre and post training surveys nearly all (98.5% and 
99.1% respectively) caretakers of children for whom AL was dispensed, reported that the health 
workers provided advice on completion of the AL treatment regimen. However, few children 
(1.5% before and 5.0% after the intervention) received all four AL dispensing and counseling 
tasks, while the performance of at least three out of four tasks increased from just 20.1% to 
34.8%.  
 
Although the above survey shows an improvement, even after training and offering job aids to 
health workers to enhance case-management practices, these figures  (on all four AL dispensing 
and counseling tasks) are too low to curb malaria morbidity and mortality among under fives. 
Therefore there is need to improve malaria treatment practices and to continuously monitor 
prescribing practices and assess availability of anti-malarials among under fives. 
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2.5. Conclusion 
This chapter reviewed the literature on malaria treatment practices, particularly in developing 
countries. It focused on prescribing patterns of AL among children under five in Uganda, 
Tanzania, Sudan and Kenya. Furthermore, it reviewed availability of anti-malarials to these age 
groups and care givers knowledge of malaria treatment in children. The literature from Kenya 
showed that malaria treatment is still at variance from the national guidelines for the diagnosis, 
treatment and prevention of malaria, suggesting that more emphasis needs to be put on AL 
prescribing adherence by health workers, and improvements in the quality of counseling to 
caregivers on malaria treatment. 
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CHAPTER THREE: AIM AND OBJECTIVES 
 3.1 Aim of research study 
 
To assess the prescribing practices and availability of anti-malarial medicines for treatment 
of children under five years of age in primary health care facilities in Bondo district. 
3.2 Objectives of research study 
 
1. To describe the prescribing practices of anti-malarial medicines for children under five 
years of age in primary health care facilities in Bondo district. 
2. To compare the prescribing practices of anti-malarials to national standard treatment 
guidelines for Malaria Treatment.  
3. To determine care givers knowledge on correct dosage, drug administration at home, 
what to do when vomiting occurs and completion of course of treatment after ACT has 
been dispensed to children under five years of age in primary health care facilities in 
Bondo district. 
 
4. To establish the availability of key anti-malarial drugs in stock at the primary health care 
facility pharmacies in Bondo district 
5. To establish the presence of a national anti-malarial treatment guideline chart in the room 
where patients are screened. 
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CHAPTER FOUR: RESEARCH METHODOLOGY 
4.1 Introduction 
This chapter describes the methods that were used to conduct the study. It includes study design, 
study population, sample size, sampling strategy including selection of the primary health care 
facilities and selection of the children under five years. It also includes data collection and 
analysis, strategies to ensure trustworthiness of data, ethical considerations and study limitations.  
4.2 Study design 
This was a facility-based descriptive cross-sectional study with the aim of assessing the existing 
prescribing practices of anti-malarials and availability of these anti-malarials to children under 
five years of age in primary health care facilities in Bondo district. The study adapted the WHO 
methodology and tools for investigating drug use in health facilities (WHO, 1993).  
4.3 Study population 
The study population consisted of all the primary health care facilities of Bondo district.  
Children from 0-59 months diagnosed with malaria and their caregivers as they attend the rural 
primary health care facilities in Bondo district constituted the secondary unit of analysis. 
 
4.4 Sample size 
A sample of 20 primary health care facilities were selected for the study and 30 care givers with 
their children who are under five were selected from each facility based on WHO 
recommendations (WHO, 1993). 
4.5 Sampling 
There are 29 primary health care facilities in Bondo district - 27 dispensaries and 2 health centres 
(MOH, 2010). Both health centres and 18 dispensaries were selected for the study.  
4.5.1 Dispensary selection strategy 
The 18 dispensaries were selected using cluster sampling of administrative units of locations. 
There are three divisions in Bondo district, namely Usigu, Maranda and Nyawita and these are 
sub-divided into administrative units (See Table 1). If the administrative unit only had one 
dispensary, then it was selected for the study. Where there was more than one dispensary in the 
administrative unit the required number of dispensaries were selected proportionally by simple 
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random sampling. For administrative units with 1-2 dispensaries, 1 was selected; 3-4 
dispensaries, 2 were selected; 5 dispensaries, 3 were selected; 6 dispensaries, 4were selected; and 
7 dispensaries, 5 were selected. The random selections were made by writing the names of the 
dispensaries of each administrative unit on pieces of paper, placing them in a hat and then 
picking the required number of dispensaries for the study from the hat. A total of 18 dispensaries 
were selected as shown in Table 1 below. Although two of the dispensaries were elevated to 
health centres during data collection, the dispensary selection strategy was implemented as 
envisaged in the proposal. 
 
Table 1: Dispensary selection strategy 
Division Administrative Unit No. of 
dispensaries 
No of selected 
dispensaries 
Usigu Western Yimbo 4 2 
North Yimbo 3 2 
East Yimbo 2 1 
Central Yimbo 2 1 
Mageta 1 1 
Maranda North Sakwa 2 1 
Western Sakwa 1 1 
South West Sakwa 1 1 
Bondo 1 1 
Nyawita Central Sakwa 7 5 
South Sakwa 3 2 
Total  27 18 
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4.5.2 Children under five years selection strategy 
A sample of 30 children under five years of age diagnosed with uncomplicated malaria and their 
care givers were selected from each facility. They were selected using the simple random 
sampling method that meant as they emerged from the consultation rooms and primary health 
care facility pharmacy they were given an opportunity to pick a folded paper with a YES or NO 
written on it from a hat. Those who chose a YES paper were interviewed and those who picked a 
NO paper were not interviewed.  
 
4.6 Data collection  
4.6.1 Data collection instruments 
Data was collected using three forms that were filled in by trained data collectors (Appendix 2) 
which were adapted from the WHO (1993) manual. 
 Form 1. Prescribing indicator form (page 49): This form captured the date, name of the 
investigator and the health care facility, division and location (administrative unit) of the health 
facility. Other sections recorded age and weight of the child and names of the various anti-
malarials, anti-biotics and anti-pyretics prescribed and dispensed for children. 
Form 2. Prescribing encounter form and Patient care form (page 50): This form was in two 
parts.  
Part A was the Prescribing encounter form that captured age, sex and weight of patient. Other 
sections were: chief complaint, diagnosis, temperature of patient, laboratory investigations, anti-
malarials and other drugs prescribed  
Part B was the Patient care form and captured details of anti-malarial drugs prescribed and 
quantity dispensed and information on labeling of drugs, care givers knowledge on dosage, drug 
administration and signs of recovery. 
Form 3.Health facility indicator form(page 51); This form captured details of selected key 
drugs in stock and presence of a national guideline treatment chart and guidelines in the 
prescription room, and the presence of an essential drug list formulary in the health care facility.  
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4.6.2 Data collection preparations and procedures 
Data collection took place during the rainy season by two research assistants who were identified 
and trained on how to fill in the forms and code the data. The research assistants were trained 
pharmaceutical technologists with a diploma in pharmacy. Data collection training for the 
research assistants was done in accordance with the WHO (1993) manual and they were trained 
by the principal researcher who holds a bachelors degree in nursing. The training included their 
role as data collectors, how to fill in the various forms, anticipation of any of the problems 
during data collection, work schedule, start and finish dates and what to expect. They were also 
trained on the anti-malarial, analgesics and antibiotics that they are likely to encounter in the 
primary health care facilities, both their generic and trade names, including dosages and provided 
with a list of anti-malarial drugs, anti-biotics and analgesics. They were also trained on the 
different names of the above drugs in the Luo language and Kiswahili. The research assistants 
were fluent in Luo and Kiswahili and collected information from patient’s care givers in the 
language in which they were most comfortable.  
 
The data collection tools were pre-tested in two different primary health care facilities in Bondo 
district that were not selected for the study and appropriate revisions and corrections were made 
before the commencement of data collection. For instance, a question to care givers on whether 
AL was dispensed in full quantity appeared to be irrelevant, given that AL was dispensed as pre-
packs (patient ready packs) from the government supplier. Instead, the researcher opted to record 
whether the full quantity was dispensed as an observation recognizing that dispensing AL in full 
quantity is the one of the cornerstones of treating malaria.  
 
4.6.3 Data management and analysis 
Once the data was collected it was checked for completeness and cleaned before leaving the 
primary health care facility. This  included spell checking, for instance on the name of anti-
malarial drugs, secondly for invalid character values e.g. gender instead of entering F or M  it is 
either missing, or lower case has been used. Thirdly, the team checked for invalid numeric 
values, for instance on the number of drugs prescribed if the data entered read 20 or age of child 
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read 1200. Coding was then carried out, for instance for gender F=1 M=2. Then the data was 
entered by the two research assistants into SPSS where summary statistics of frequencies, means 
and percentages were calculated to describe all outcomes relating to prescribing practices and 
availability of medicines. Results have been presented in tables and charts.  
 
4.7 Validity and reliability  
Validity relates to whether the results of the research are consistent with the data collected from 
the study. It also considers the likelihood of a given measurement procedure giving the same 
results if the exercise is repeated (Merriam, 1998). To ensure validity, the researcher trained the 
two research assistants together to guarantee uniformity of data collection. The research 
assistants were pharmaceutical technologists who have an understanding of primary health care 
facilities and drugs used in treatment of malaria, they were then allowed to practice together to 
ensure consistency in the data collection, checking and coding procedures. Furthermore, a pilot 
study was carried out to pretest the data collection tools. The researcher ensured that the 
translation from English to Dholuo or Kiswahili was uniformly done to obtain the same outcome. 
To ensure reliability the researcher used standardized tools adapted from WHO (1993) for data 
collection.  
 
4.8 Generalisability 
The researcher ensured generalisability of the study by including an adequate population sample 
size as recommended by WHO to represent the entire population of Bondo district, that is, 30 
children under five years with their care givers from 20 primary health care facilities (WHO, 
1993). 
 
4.9 Limitations 
During data collection several limitations were experienced.  Firstly, some of the health care 
facilities were in remote areas and could only be accessed by a motor bike especially when it 
rained. This affected duration of data collection since the data collectors had to arrive late 
extending hours of data collection hence more days of collecting data. Secondly, a few health 
care facilities were on an island and were only be accessible when the tides were low making it 
weather dependant. This affected the schedule for data collection since the research assistants 
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had to collect data within a specified time as the motor boats have a specific time departing and 
arriving at the island. Due to poor accessibility in remote health care facilities and especially on 
the island, it further extended the days of collecting data making it more expensive for the 
researcher. Thirdly, some of the care givers had ‘research fatigue’. This was because research in 
different fields including HIV and, STIs had been carried out in Bondo District so clients are 
tired of being part of research studies. This as well extended the duration of data collection since 
we had to wait for more clients to get the required number of care givers for the particular health 
care facility.  Lastly,  five care givers in a certain health care facility felt they should be paid to 
give information as they feel these studies being done in Bondo are getting external funding and 
more so some of the NGOs at times offer incentives to care givers like mosquito nets etc. 
therefore the research assistants had an uphill tasks to convince the care givers that this research 
was purely for academic research and this in the end consumed time intended for data collection 
by prolonging data collection period by a day. All in all the willing care givers were convinced 
and so the data was eventually collected.  
 
4.10 Ethical considerations 
Ethics is about what is right or wrong in human conduct. Ethical issues are of particular 
relevance in research during data collection as well as when publishing the findings (Merriam, 
1998).  Before embarking on the field trip to the institutions, the researcher obtained ethical 
approval from both the local ethics and review committee, that is, the University of Nairobi and 
Kenyatta National Hospital ethics review committee and University of the Western Cape 
Research and Ethics Committee (Appendix 3 and 4). The researcher also obtained permission 
from the District Medical Officer who is in charge of all health care facilities in the district. 
Written approval was obtained and given to the primary health care facilities in charge 
(Appendix 5). Informed consent was obtained as well from the care givers of the children 
interviewed in different health care facilities that were part of the study within Bondo district 
(See Appendix 6 and Appendix 7). During interviews with the care givers Dholuo was used as 
the main language as majority of patients were Luo speaking. 
 
Regarding patient and facility confidentiality, the data collected and coded was only available to 
the researcher. The data was locked in a cabinet and the researcher was the only one with the key 
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to the cabinet. The data in the computer was protected by use of a password only known by the 
researcher. In addition the data collected is presented as aggregated data for Bondo district and 
individual facilities are not identified. The results have been disseminated to the relevant 
authorities including the District Medical Officer, district pharmacist, senior nurse, 
representatives from NGO’s and mission hospitals of the facilities surveyed and the National 
Council for Science and Technology.  
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CHAPTER FIVE:  RESULTS  
5.1 Introduction 
This chapter presents the findings of the study which was to assess the prescribing patterns of 
anti-malarials to children under five years of age at primary health care facilities in Bondo 
district and compare these practices to the National Guidelines for the Diagnosis, Treatment and 
Prevention of Malaria. In addition, the study assessed the quality of dispensing and counseling 
services and the availability of anti-malarials and guidelines at the facilities. A total of 600 
patients (under five years of age children) diagnosed with uncomplicated malaria and prescribed 
with anti-malarials, their care givers consented and took part in the study, 63.5% were females 
while 36.5% were males. The results are further presented in frequency tables and graphs.  
 
5.2 Description of study participants 
The gender and age of the study participants who were children under five years and diagnosed 
with uncomplicated malaria are shown in Table 2 below. More females participated in the study 
(380) compared to their male counterparts (220). Importantly, males and females of the age 
group between 37-60 months were more compared to other age groups. 
 
Table 2: Distribution of age and sex of participants (N= 600)  
Gender 
Age Group(Months)   
1-12 
months 
13-36 
months 
37-60 
months 
Not 
Stated Total 
Female 
Count 119 123 137 1 380 
% 31.3% 32.4% 36.1% 0.3% 100.0% 
Male 
Count 45 50 124 1 220 
%  20.5% 22.8% 56.6% 0.0% 100.0% 
Total 
Count 164 173 261 2 600 
%  27.4% 28.9% 43.6% 0.2% 100.0% 
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Table 3: Distribution of age and weight of the participants (N=600) 
 
Age 
Group(Months)   
Weight in Kg   
5-14 15-24 25-34 Not Stated Total 
1-12 months 
Count 151 10 0 3 164 
%  92.1% 6.1% 0.0% 1.8% 100.0% 
13-36 months 
Count 142 13 0 18 173 
%  82.1% 7.5% 0.0% 10.4% 100.0% 
37-60 months 
Count 31 206 6 18 261 
%  11.9% 78.9% 2.3% 6.9% 100.0% 
Not Stated 
Count 2 0 0 0 1 
%  100.0% 0.0% 0.0% 0.0% 100.0% 
Total 
Count 326 229 6 39 600 
%  54.3% 38.2% 1.0% 6.5% 100.0% 
 
 
The results in Table 3 above show that a large percentage of children’s weights were taken which 
is in line with the national treatment guideline. However, 10.4 % (18) of the children between the 
ages of 13-36 months were not weighed and 6.9 % (18) between 37-60 months were not weighed 
either. Although the percentages look small, this trend remains critical.  
 
5.3 Reported health problems  
Figure 2 shows the percentage of the study participants reporting with various signs and 
symptoms.  Fever (body temperature higher than 36.5 degrees Celsius) was reported in all 
participants, followed by refusal to feed or breast feed (90%). Coughing, vomiting and headache 
were reported in just under half of the participants.  
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Figure 2 : Reported Health problems: signs and symptoms (N=600) 
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5.4 Diagnosis and prescribing procedures 
Table 4 indicates diagnosis procedures undertaken by the health workers. In all cases children’s 
age, temperature and laboratory tests were taken and recorded in their respective medical records 
books, however a small percentage of the children, 6.5%, did not have their weight taken. This is 
critical as weight is used to determine the dosing schedule for artemether-lumefantrine (AL), the 
anti-malarial of choice for uncomplicated malaria in children. 
Table 4 : Recorded diagnosis procedure ( N=600) 
 
 No (%) 
Age  600 (100%) 
Weight  561 (93.5%) 
Temperature   600 (100%) 
Laboratory diagnosis 600 (100%) 
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The results from the table above indicate that diagnosis procedures were in conformance with the 
national treatment guidelines in the vast majority of participants.  
 
Table 5: Anti-malarial and other medicines prescribed to participants ( N=600) 
 
 Anti-malaria Analgesics Anti-biotics 
AL 595(99.2%)   
Quinine 5(0.8%)   
Paracetamol  595(99.2%)  
Amoxicillin   512(85.3%) 
Metronidazole   22(3.7%) 
Nystatin Oral suspension   11(1.8%) 
Cotrimazole   33(5.5%) 
Tetracycline eye ointment   11(1.8%) 
 
Table 5 above shows that almost all participants were prescribed for AL as a first line for 
treatment of malaria, however, there were a small percentage of participants, 0.8% of the 
children, who presented with uncomplicated malaria and were prescribed quinine. This is not in 
accordance with the National Guidelines for the Diagnosis, Treatment and Prevention of Malaria 
in Kenya. An analgesic, paracetamol was largely prescribed for fever, which is in line with the 
guidelines. Secondly, there are children who were also diagnosed with other infections hence 
prescribed for other drugs which included amoxicillin, cotrimazole, nystatin oral suspension, 
metronidazole and tetracycline eye ointment. Amoxicillin was the preferred choice of antibiotic 
prescribed for most coughs that were reported, followed by cotrimazole syrup. Nystatin oral 
suspension was prescribed to children who presented with oral thrush while metronidazole was 
dispensed to children who complained of diarrhea; lastly tetracycline eye ointment was 
dispensed to children who complained of purulent discharge from their eyes. 
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5.5 Quality of dispensing and counseling of AL 
5.5.1 Dispensing of AL as observed  
In all cases AL was dispensed in full quantity in pre-packed blisters as received from the 
government suppliers. They are packed according to weight of patient (weight 5kg to less than 
15kg and 15kg to less than 25kg for children under five years) see Appendix 8 and 9.  
The name of the drug and the strength are labeled in red (Coartem, Dispersable-
Artemether/Lumefantrine 20mg/120mg). There is a sign of the moon and the sun -where the 
moon means the drug to be taken in the evening while the sun means drug to be taken in the 
morning. An additional feature noted on the blister pack was a sample of malaria parasite 
appearance in blood from the 1
st
 dose to the last day of taking medication (1
st
 day the malarial 
parasites are numerous in blood, on the 2
nd
 day they are scanty while  on the 3
rd
 day there are 
none). However there is no space for the dispenser to write the patients name or dispensing date 
on the blister packs and so none of the AL dispensed were labeled adequately. Also, most of the 
other drugs dispensed alongside AL were not labeled either.  
 
5.5.2. Reported counseling and understanding of caregivers   
Table 6: Reported counseling and understanding of care givers (N=600) 
 
Reported counseling and understanding of care givers  No (%) 
Tell me which of these drugs is used to treat malaria(AL) 590 (98.3%) 
Childs first dose of anti-malaria given at the health facility 267 (44.5%) 
Dispenser observed swallowing of first dose 243 (40.5%) 
Dosing schedule explained  580 (96.7%) 
Importance of completing anti-malarial course 490 (81.7%) 
Told what to do when your child vomits 20 (3.3%) 
 
Table 6 above shows that 98.3% of caregivers in the study were aware that AL is the drug of 
choice to treat malaria, while 44.5% of children were given first dose of AL at the health care 
facility as supervised by the dispenser and 40.5% of the children were observed by the dispenser 
when swallowing their first dose of AL in the health facility. What was seen during data 
collection is that some are given instruction to go to the water drinking point and give the 1
st
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dose to the child while some care givers are just told to go and give the drug at home. 
Additionally, the care givers were assessed on their understanding of malaria treatment as given 
at the health care facilities with the health care providers. A high percentage of caregivers 
(96.7%) knew how to give their children medicine at home as explained to them by the drug 
dispensers who in this case were either nurses or pharmaceutical technologists. Secondly, a high 
proportion of the care givers were told on the importance of drug completion.81.7%. However, 
only 3.3% of the care givers were told what to do when their children vomited the drug after 
administration as described in the national treatment guideline. 
 
5.6  Availability of anti-malarials and guidelines  
Table 7 shows that all of the health care facilities in the study had all key anti-malarials in stock 
at the time of data collection.  
 
Table 7: Availability of anti-malarials and guidelines at health facilities ( N= 600 ) 
 
Health facility indicator No (%) 
 
All key anti-malaria drugs in stock  20 (100%) 
AL dispensing wall charts exposed 20 (100%) 
Algorithm for assessing and treating children under 5yrs exposed 20(100%) 
Booklet with miniature case management wall charts available 20(100%) 
Folder recommending presumptive treatment of childhood fevers 
with AL available 
19(95%) 
Poster recommending presumptive treatment of childhood fevers 
with AL available 
20(100%) 
Essential drug list formulary present in the facility 19(95%) 
 
This included AL (in different pack sizes of 1, 2, 3, and 4 drug blister packs), which is the first 
line drug for uncomplicated malaria in adults and children; quinine injections used for severe 
malaria in both adults and children and Sulphurdoxine Pyremethamine (SP) is used for malaria 
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prophylaxis in pregnant women. The malaria treatment guidelines and charts were on the walls 
of all the health care facilities as indicated in the table below. A small percentage of health care 
facilities (0.5%) did not have a folder that recommends presumptive treatment of childhood 
fevers with AL. In addition, 0.5% of the facilities did not have essential drug list formulary as 
well.  
 
5.7 Conclusion 
This chapter has covered the outcomes of the study carried out in Bondo district. It has explored      
description of study participants, health problem as reported by the care givers, prescribing  and 
diagnostic procedures , quality of dispensing  AL and counseling services offered , availability of  
AL in adequate  stock  and presence of wall charts with the course of action from  National  
Guidelines for the, Diagnosis, Treatment and Prevention of Malaria. The next chapter will 
discuss these findings. 
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CHAPTER SIX: DISCUSSION 
 6.1 Introduction 
This chapter discusses the results in the light of the Kenya National Guidelines for the Diagnosis, 
Treatment and Prevention of Malaria and published literature. The overall findings revealed that 
almost all (99.2%) of children under five with uncomplicated malaria in this study were 
prescribed AL, as recommended by the national guidelines. It was pleasing to note that AL and 
other anti-malarial drugs were in stock at all the selected primary health facilities at the time of 
the study. In addition, diagnosis and prescribing procedures as per the guidelines were adhered in 
majority of cases, with the exception of 6.5% of patients whose weights were not taken and 
recorded by health workers. AL was dispensed in blister packs with appropriate instructions for 
administration to all patients with the prescriptions, however, labeling remained a serious 
challenge as none of the drugs dispensed, including AL, were labeled with patients name or date 
of dispensing. This contrary to recommended practice could compromise treatment. The quality 
of counseling provided to caregivers was mixed, with some gaps that need to be addressed.  
 
The chapter discusses the findings under the following sub headings; reported health problems, 
recorded diagnosis procedures, anti-malarials and other medicines prescribed, dispensing of 
Artemether Lumefantrine (AL) observed, reported counseling and understanding and availability 
of anti-malarials.  
 
6.2 Reported health problems 
The study found out that 100% of the patients presented with fever, 90% of the children refused 
to feed/breast feed and other symptoms such as coughing ,vomiting and headache were common. 
These symptoms are in line with the National Guidelines for the Diagnosis, Treatment and 
Prevention of Malaria which states that uncomplicated malaria is characterized by fever in the 
presence of parasetemia. Other symptoms mentioned included chills, profuse sweating, muscle 
pains, abdominal pain, diarrhoea, nausea, vomiting and irritability. The guidelines further says 
that the symptoms may present singly or combination (DOMC, 2010). Kamuhabwa and Ramji 
(2011) in a study from Tanzania also reported fever (90%) as the most common health problem 
among children under five with uncomplicated malaria. Similarly, Mannan, Malik and  Ali  
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(2009) and Zurovac et al (2008) describing studies from Khartoum and Uganda respectively 
reported fever in 77.6% and 83.2% of patients with malaria. 
 
6.3 Recorded diagnosis procedures  
The study found that, in general, diagnostic procedures were followed as per the national 
treatment guideline. The patients’ age, temperature and laboratory investigations were taken and 
recorded in all the patients interviewed. However, although the child’s weight was taken in 
93.5% of the cases, in 6.5% of the children their weights were missing. This was probably due to 
the heavy work load experienced by health workers observed in most of the health care facilities 
during data collection. The National Guidelines for the Diagnosis, Treatment and Prevention of 
Malaria recommends that the weight of the child must be taken as the treatment dosage of AL is 
pegged on the weight of the child. This is particularly important for children under five years of 
age as failure to have accurate weight could lead to under dosing or overdosing a child with AL  
hence  treatment failure, drug resistance and even relapse of malaria. 
 
Contrary to the study findings, a similar study in Tanzania found that all the children had their 
weights taken and did not weigh less than 5kg (Kamuhabwa and Ramji 2011). If a patient’s 
weight is not taken or recorded it could be attributed to a number of factors including lack of 
scales or heavy work load of the health workers. Ucakacon et al (2011) suggested in his study 
that patient work load was one of the factors that could influence the prescribing habits of health 
workers more so in an African setting.   
 
6.4 Anti-malarials and other medicines prescribed 
Although AL was prescribed to 99.2% of the children, 0.8% were prescribed quinine. 
The National Guidelines for the Diagnosis, Treatment and Prevention of Malaria recommends 
AL as the first line drug for treatment of uncomplicated malaria in children with quinine 
recommended for treatment of complicated or severe malaria. In this study the 0.8% that were 
prescribed for quinine were not admitted with complicated or severe malaria nor did they present 
with the complicated or severe in the outpatient clinics in the health centers, implying that these 
cases were not adherent to treatment guidelines.  
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Available literature from earlier studies carried out in Kenya (Juma and Zurovac, 2011) reported 
that of the 63.6% of children under five who presented with fever, 9% were treated with non-
recommended quinine or combination of AL and quinine contrary to the national treatment 
guideline. We can therefore notice from the comparison of these studies that the trend of 
prescribing quinine by health workers without complying with the treatment guideline is still 
occurring. This view is supported by other surveys done in Bondo district and four other endemic 
areas in Kenya which revealed that adherence by health workers on the treatment guideline was 
low (Chuma et al, 2010). Zurovac et al, (2008) revealed in his survey in Kenya that 1.9% of 
children under five with uncomplicated malaria were prescribed quinine. In the wider East Africa 
region a similar study in Tanzania revealed an even a higher percentage (35.5%) of the children 
were prescribed for quinine yet they did not present with complicated or severe malaria 
(Kamuhabwa and Ramji, 2011). In Uganda, 4% of the patients were prescribed quinine yet the 
national treatment guideline recommends AL as first line drug for treatment of uncomplicated 
malaria and not quinine (Zurovac et al 2008). 
 
This study also revealed that most children received other medicines in addition to anti-malarials. 
These included paracetamol, anti-biotics, metronidazole, nystatin oral drops and tetracycline eye 
ointment. Instructively, paracetamol was prescribed as is required by the national treatment 
guideline. Other studies in Tanzania, Uganda, and Khartoum also confirmed that patients were 
prescribed analgesics for control of fever and headache (Kamuhabwa and Ramji, 2011; Zurovac 
et al 2008; Mannan et al 2009).  
 
The National Guidelines for the Diagnosis, Treatment and Prevention of Malaria also encourage 
health workers to advise care givers on other mechanical ways to reduce fever such as tepid 
sponging and exposure to fresh air. This study revealed that the majority of patients were 
dispensed paracetamol syrup but the other mechanisms, were not shared with the care givers, 
possibly owing to the patient work load experienced in most of the health care facilities. These 
results are in line with a study conducted in Khartoum where a majority of patients especially 
children under five who were diagnosed with uncomplicated malaria were prescribed 
antipyretics whist the researcher argues that other mechanisms as mentioned above are more 
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effective and ought to have been offered to the care givers as opposed to drugs (Mannan, Malik 
and Ali, 2009).  
 
Antibiotics were prescribed and dispensed to all patients who additionally presented with a 
cough. This could indicate irrational use of antibiotics because some coughs could be viral and 
may not necessarily need anti-biotics. In addition according to the national guidelines for the 
diagnosis, treatment and prevention of malaria in Kenya, diarrhoea is listed as one of the 
symptoms that children with malaria would present with clinically (MPHS & MMS, 2010). In 
this particular study, children who presented with diarrhoea, metronidazole was prescribed 
without a confirming stool laboratory test which is an example of irrational prescribing.  
 
6.5 Dispensing of AL observed 
Dispensing is an important step in ensuring anti-malarial drug accessibility, affordability, safety 
and rational use (Mannan, Malik and Ali, 2009). In this study AL was prescribed and dispensed 
in full quantity to all children. They were supplied in pre-packed blisters which were available in 
two categories for children under five years of age (5kg to less than 15kg and 15kg to less than 
25kg). The blister packs incorporate several features to facilitate drug adherence among the care 
givers and patients with malaria. The malaria parasites are illustrated on the blister pack how 
they appear in blood from the first day when drug administration is commenced (more parasites 
in the blood) to the third day when drug is completed (no malaria parasite). This is to put 
emphasis to care givers that for a child to be completely cured and well, all the doses must be 
given. Additionally, the illustration of the sun and moon on the blister pack guides illiterate care 
givers on what time to give their children the drug since the sun means the drug should be given 
in the morning while the moon means evening. 
 
However, one of the problems with the blister packs was that they did not have space for the 
dispenser to label them with the name of the patient. This could lead to the drug being given to a 
wrong patient in cases where there is more than one child being attended to by one care giver. 
Moreover, where its one child dispensed with unlabeled syrup, the caregivers might not 
remember the frequency of administering the drug leading to under dose or over dose. 
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6.6 Reported counseling and understanding of caregivers  
The importance of counseling patients and caregivers on malaria treatment has been clearly 
described in the National Guidelines for the Diagnosis, Treatment and Prevention of Malaria. It 
advises that health workers need to directly observe the first treatment dose at the health facility 
which may be given on an empty stomach. Secondly, the care givers ought to be shown how to 
prepare the dispersible tablets before administration and this should be done before they leave 
the health facility, thirdly, if vomiting occurs 30 minutes after drug administration the dose 
should be repeated and lastly the emphasis should be put on dosage completion even if the 
patient feels better after taking a few doses. In addition care givers need to be advised that incase 
the child’s condition gets worse, then they should go back to the health care facility (DOMC, 
2010). 
   
In this study counseling given to the caregivers by the health workers was of variable quality. 
The study showed that 98.3% knew that AL is the drug of choice for treating malaria -which is 
very good, however only 44.5% were given first dose at the health facility, and 40.5% were 
observed by the dispenser swallowing their first dose. Whilst, 96.7% had the dosing schedule 
explained to them and 81.7% were told of the importance of completing the course of treatment, 
only 3.3% were told what to do when their children vomited after administration of AL, which is 
worrisome.   
 
The above results indicate that the quality of patient care and counseling remains an area of 
concern and there is an urgent need to address the counseling services that ought to be offered to 
the care givers. The number of the patients who were administered to AL and swallowing 
observed by the dispenser at the health care facility was still low (40.5%) although there was a 
marked improvement compared to earlier studies done in Bondo by (Wasuna et al, 2010) ,where 
the pre-training and post training survey found figures of  21.6% and 33.6% respectively.  
 
For instance, of the counseling services assessed there is need to educate the care givers on what 
to do when their children vomit within 30 minutes after AL administration. This advice was only 
availed to 3.3% of the patients. According to Wasuna et al, (2010) the pre and post training 
surveys of counseling services done in Bondo district revealed that only 3.3% and 8% 
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respectively were given advice on what to do when vomiting occurs. This is a worrying trend 
because vomiting does occur fairly frequently and the therapeutic effect needed to kill the 
malaria parasite may not be achieved if the vomited drug is not repeated. This in the end will not 
aid Kenya achieve its Abuja target of eradicating malaria by 2017. Similar trends are seen in 
studies done in Sudan (Mannan, Malik and Ali, 2009), Uganda (Zurovac et al, 2008) and 
Tanzania (Kamuhabwa and Ramji, 2011). These high numbers from the study are due to heavy 
work load on the few health workers as witnessed at most of the health care facilities during data 
collection. This perhaps shows heavy workload affects compliance to the guidelines. Another 
reason is thought to be, lack of adequate training on the need for providing supportive care and 
counseling services to the care givers. 
 
6.7 Availability of anti-malarials and guidelines at health facilities 
The research study revealed that all the health care facilities had adequate stock of the anti-
malarias which included AL, Quinine and SP. AL was prescribed as a first line treatment for 
uncomplicated malaria and it was available in all the health care facilities. Secondly, quinine was 
available too for complicated and severe malaria and in adequate stock. The only setback was 
that a few health officers prescribed it to the children with uncomplicated malaria which ought 
not to be done. SP was available for prophylaxis in pregnant women. These findings are different 
from similar research done in Bondo and elsewhere. Chuma, Okungu and Molyneux, (2010) 
reported AL stock outs in four districts in Kenya, which included Bondo. Similarly, Wasuna et al 
(2008), reported that Bondo had a stock out of AL drugs from December 2006 to February 2007 
and health workers indicated that they  rationed drugs because they were not certain when the 
next drugs would be supplied. 
 
The availability of anti-malarials in this study were contrary to those of a similar study in Bondo 
district during 2009 where it  found that AL stock outs were experienced majorly during the 
rainy season when malaria infections were high (Chuma et al, 2010). According to Noor et al 
(2005) poor road network is a factor that influences availability of anti-malarial drugs during wet 
seasons. This hinders not only the patients in getting the anti-malarial treatment but also the 
health care providers who might not report to work due to remote and inaccessibility of the 
health care facility to provide anti-malarial treatment needed. During the data collection phase of 
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this study confirmed some of these challenges in that several of the more remote facilities could 
only be accessed by motor bikes especially during the wet season, and the islands were only 
accessible when the tides are low. However, encouragingly none of the care givers reported 
instances where AL was unavailable nor did a facility report lack of at least one health care 
provider due to rain and road inaccessibility.   
 
The findings from this research study show a marked improvement on availability of AL and 
other anti-malarial drugs in all the health care facilities that were assessed compared to other 
research findings that were conducted earlier. The treatment guideline charts were present in all 
the health care facilities except for one facility. This too is contrary to similar studies done in 
Sudan where the guideline wall charts were available in 70.8% of the health care facilities 
assessed (Mannan, Malik and Ali, 2009).  
 
On the whole, the study findings reported a significant improvement compared to the previous 
surveys may be due to vigorous campaigns by the division of malaria control programme and 
implementing various recommendations from past research. In spite of this progress, it is crucial 
to implement recommendations suggested in this study as well to improve counseling services 
offered to the care givers so as to avoid malaria relapse, drug resistance and more so reduce both 
morbidity and mortality rates among children under five to help Kenya achieve its Abuja target 
by 2017. 
 
 
 
 
 
 
 
 
 
 
 
39 | P a g e  
 
CHAPTER SEVEN: CONCLUSIONS AND RECOMMENDATIONS 
 
This chapter gives a summary of the research outcome. It further suggests ways to improve 
prescribing patterns and quality of dispensing artemether lumefantrine (AL), and counseling 
practices to children under five years with uncomplicated malaria in line with the National 
Guidelines for the Diagnosis, Treatment and Prevention of Malaria  
 
7.1  Conclusions 
 
The research found that prescribing of AL in Bondo district to children under five as first line for 
the treatment for uncomplicated malaria was largely in line with recommendations in the 
guidelines. However, a very small percentage of the children (0.8%) were prescribed for quinine 
which is not recommended for uncomplicated malaria. 
The research further discovered that the majority of care givers knew that AL is the drug of 
choice for treatment of uncomplicated malaria. On the other hand, advice on drug administration 
at home and what to do when a child vomits was very poor indicating that the quality of 
dispensing and counselling practices needs to be improved further in these health care facilities.  
It was very encouraging to find that key anti-malarial drugs were in stock in all the 20 health care 
facilities and the national treatment guideline charts and other relevant charts pertaining to AL 
prescription and patient care were well placed on the walls where patients are being screened in 
95% of the facilities. 
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7.2  Recommendations 
The result of the study identifies a few areas that need to be attended to so that optimal results 
are achieved. These include;  
1. Further training of health workers at facilities regarding adherence to malaria treatment 
practices at the facility and the advice they give to care givers  
2. Continuous training of staff on the importance of adhering to the National Guidelines for the 
Diagnosis, Treatment and Prevention of Malaria, including rational prescribing of antibiotics. 
3.  Regular monitoring of anti-malarial availability at health facilities.  
4. Employment of more health workers in the rural health facilities to cope with heavy 
workloads. 
5. Educate the rural community and especially the caregivers in Baraza’s (community 
meetings) on supportive care when children are on treatment of AL, as is indicated in the 
treatment guideline as the time they are attended to in the health care facility is limited and so 
not much can be discussed regarding supportive care. 
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APPENDICES 
Appendix 1: Artemether lumefantrine treatment regimen 
Weight 
in kg 
Age in 
years 
Number of tablets per dose 
Day 1 Day2 Day 3 
1St 
dose 
8hrs 24hrs 36hrs 48hrs 60hrs 
5-14 5months< 
3 years 
1 1 1 1 1 1 
15-24 3-7years 2 2 2 2 2 2 
25-34 8-11 
years 
3 3 3 3 3 3 
Above 
34  
>12years 4 4 4 4 4 4 
 
Copied from the National Guidelines for the Diagnosis, Treatment and Prevention of Malaria in 
Kenya. (DOMC, 2010) 
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Appendix 2 : Data collection tools. 
FORM 1. PRESCRIBING INDICATOR FORM
Division……………………................................................................... Research assistant…………………………………………...
Adminstrative Unit………………………………….........................................
Location (Administrative unit)..........................................................
Name of health facility………………………………….....................................
Date……………………..............................
No Age of pt Weight of 
patient(Kg)
Diagnosis of 
patient(state)(
M=Malaria,O=
Other)
Artemesini
n 
lumefantrin
e 
prescribed 
and 
dispensed(P
D=Prescrib
ed and 
dispensed,P
ND=Precri
bed and not 
dispensed).
Other anti-
malarials precribed 
and 
dispensed.(PD=Pre
scribed and 
dispensed,PND=Pr
escribed and Not 
dispensed)
Anti-pyretic 
drug  
prescribed(P=P
aracetamol,I=I
boprufen).
Anti-
pyretic 
drug 
(prescr
ibed  
and 
dispens
ed=PD,
prescri
be and 
not 
dispens
ed=PN
D)(P=P
araceta
mol,I=I
bopruf
en
Reason why 
drugs not 
available in the 
health facilty(S= 
out of stock, M= 
not enough 
money, H= have 
at home, W=do 
not want, 
O=other)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30  
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FORM 2(A). PRESCRIBING ENCOUNTER  FORM
1.Division………………………………………………………Research Assistant…………………………………….
Adminstrative Unit……………………………………..
Name of Health Facility………………………………………………………………………Date …..
2.Name(Initials)………………………… Date………………………………………Sex …… Age………………. Weight……….. Prescriber………………
1.Health Problem(signs and symptoms). Yes      |     No. (Tick)
i).Headache
ii)Fever
iii)Refusal to feed/breast feed
iv)Other
1.Yes…(specify)
2.No………….
1..Yes(specify)……………
2.No…...…………..
4.Diagnosis
1……………………………
………
2……………………………
………
3…………………………..
5.Anti-malarial precsribed 1…………………………………Strength………….. Dose………………… Quantity……………
6. All other drugs prescribed 1…………………………………………Strength ………………..Dose………………. Quantity…………………..
2……………………………………………..Strength ……………..Dose………………. Quantity…………………..
3……………………………………….Strength…………………..Dose………………. Quantity…………………..
4……………………………………………..Strength ……………..Dose………………. Quantity…………………..
5…………………………………………Strength ………………..Dose………………. Quantity…………………..
6……………………………………………….strength …………..Dose………………. Quantity…………………..
2(B).PATIENT CARE FORM
Name of drug prescribed Full quantity 
dispensed (Y/N)
If no, give reason (S= out 
of stock, M= not enough 
money, H= have at home, 
W=do not want, O=other)
If no, told where to buy 
medicines (Y/N)
Labelling of all medicines
Correctly labelled patients 
name (Y/N)
Correct dosage(Y/N) Correct strength 
(Y/N)
Total quantity of the 
drug dispensed  
correctly(Y/N)
Correct  treatment 
frequency(Y/N).
Care giver 
identifies 
antimalaria 
dispensed to 
the child (Y/N).
First dose of 
anti-malarial 
given to the 
child at the 
health 
facility(Y/N)
Drug dispenser 
observed 
swallowing of 
first dose(Y/N)
Dosage to take 
home 
expalined(Y/N)
State the 
advice given 
to the care 
giver
Adivice on 
what to do 
when the child 
vomits 
given(Y/N)
State the advice 
given to the care 
giver.
Adice on 
comlpletion of 
treatment regimen 
given(Y/N)
State the 
advice given to 
the care giver 
on treatemnt 
regimen.
1
2
3
4
5
6
Total No of drugs
2.Temprature done
3.Laboratory Investigations done
Antimalarial medicine treatment & advice given 
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FORM 3. HEALTH FACILITY INDICATOR FORM:
Division…………………................................................................... Research assistant…………………………………
Adminstrative unit………………………………….........................................
Name of health facility.....................................................
Date………………………………….....................................
 
3.1.KEY DRUGS
No Ant-malarial Strength Pack size Available(Y=Yes,N=No).
1 AL
2 SP
3 Q
3.2.MALARIAL GUIDELINES
No AL dispensing wall charts 
exposed(Y=Yes,N=No).
Algorithm for 
assessing and treating 
children under five 
years 
exposed(Y=Yes,N=
No).
Booklet with 
miniature case 
management wall 
charts 
available(Y=Yes,N=
No).
Folder recommending 
presumptive treatment of 
childhood fevers with AL 
available (Y=Yes,N=No).
Poster recommending 
presumptive treatment of 
childhood fevers with AL 
exposed(Y=Yes,N=No). 
Essential drug list 
formulary  present in the 
facility (Y=Yes,N=No).
1
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Appendix 2.1 :Patient care structured interview form (English) 
Form 2b: Patient care structured interview 
 
Division……………………………….  Research Assistant…………………….. 
Administrative Unit……………….....  Date…………………………………….. 
Health Facility……………………….. 
 
Name (Initials)…………….Date…………….Sex…………Age…………….Weight…………… 
Prescriber………………. Dispenser……………… 
  
1. Please tell me the names of all the drugs (medicines) that have been prescribed for your child 
today? 
1……………………….. 
2……………………….. 
3………………………. 
4………………………. 
2. Was the full quantity dispensed for all the drugs? 
Drug 1…………. Yes/No/Do not know 
Drug 2………… Yes/No/Do not know 
Drug 3…………. Yes/No/Do not know 
Drug 4…………. Yes/No/Do not know 
3. If No, kindly give reasons (mark ALL reasons mentioned, may be more than one reason) 
S= not in stock; M=not enough money; H=have at home; W=do not want; B= told to buy 
drugs; O=other (specify) 
 
Drug 1…………………………  
Drug 2…………………………  
Drug 3………………………… 
Drug 4………………………….  
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LABELLING 
4. My I see all the drugs you have received today for your child.  
(Read the labels and tick if the information appears on the labels) 
Drug Strength Dose Total 
quantity 
Patient 
name 
Facility 
name  
Date 
Drug 1       
Drug 2       
Drug 3       
Drug 4       
 
5. Please tell me which of these drugs is to treat malaria (the anti-malarial). 
 
Name of drug……………………… OR Do not know………..      
 
(Write answer given by care-giver. If care-giver cannot identify anti-malarial drug, or 
incorrectly identifies, tell them which one is the anti-malarial drug, so they can complete 
the remainder of the questions) 
 
The rest of these questions are about this drug (medicine) 
 
6. Was your child’s first dose of anti-malarial given at this health facility today? 
Yes  
No  
7. Did the drug dispenser observe swallowing of your child’s first dose? 
Yes  
No  
8. Was the dosage to be given to your child at home explained? 
Yes  
No  
 If yes, please explain  
……………………………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………….. 
…………………………………………………………………………………………………………………………………….. 
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9.  Were you told what to do if your child vomits after taking the anti-malarial drug?  
Yes 
No 
If yes, please explain 
……………………………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………… 
10. Were you told about the importance of completing the anti-malarial drug regimen?  
Yes 
No 
If yes, please explain 
………………………………………………………………………………………………………
………………………………………………………………………………………………………
… 
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Appendix 2.2: Patient care structured interview form(Kiswahili) 
Mahojiano ya kina kuhusu huduma anayopewa mgonjwa 
 
CHUO KIKUU CHA CAPE MAGHARIB 
 Private Bag, x 17 Bellville 7535, AFRIKA KUSINI. 
 Tel;+27 21-959, Fax 27 21-959 2630 
Barua pepe; hbradley@uwc.ac.za 
Idara………………………..  Mtafiti  msaidizi………………………………. 
Kitengo simamizi………………………………. Tarehe………………………. 
Kituo cha afya………………………………………………………. 
Jina……………………….Tarehe……………Jinsia……….Umri…………...Uzito……………. 
Mhudumu…………….Mpeaji dawa………………. 
1. Tafadhali niambie majina ya madawa ambazo mtoto wako amepewa leo? 
1……………………….. 
2……………………….. 
3………………………… 
4………………………… 
2.   Je, ulipewa idadi kamili ya tembe unayohitaji? 
            Dawa ya 1……………….Ndio/La/Sijui 
            Dawa ya 2………………..Ndio/La/Sijui 
            Dawa ya 3………………...Ndio/La/Sijui 
             Dawa ya 4………………..Ndio/La/Sijui 
3.   Kama la tafadhali toa sababu  
S=Dawa hazikuwa; 
M=sikuwa na hela za kutosha;  
H=niko na dawa nyumbani;  
W= Hatutaki dawa;  
B= niliambiwa ninunue dawa kwingine;  
O= sababu nyingine 
KUIPATIA MADAWA YA MALARIA NA MENGINE: 
4. Naomba kuona madawa ambazo umepokea leo kwa niaba ya mtoto wako. 
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Dawa Nguvu Kiwango Jumla ya 
kiwango 
Jina la 
mgonjwa 
Jina la 
zahanati 
Tarehe 
Dawa ya 1       
Dawa ya 2       
Dawa ya 3       
Dawa ya 4       
 
5. Tafadhali niambie gani kati ya dawa hizi ni ya kutibu malaria. 
Jina la dawa………………………. AMA Sijui………………………. 
6. Je, ulipewa madawa ya malaria ya kwanza ya mtoto wako katika hospitali hii? 
Ndio  
La  
7. Je, mhudumu alichunguza umezaji wa tembe za kwanza za mototo wako? 
Ndio  
La  
8. Je, uliambiwa kipimo cha dawa cha kumpa mtoto nyumbani? 
Ndio 
La  
Kama ndio tafadhali 
fafanua………………………………………………………………………………………………
………………………………………………………………………………………………………
……………………………………………………………………………………………………... 
9.  Uliambiwa la kufanya iwapo mototo atatapika baada ya kumeza tembe za malaria? 
Ndio 
La 
10. Je, uliambiwa umuhimu wa kukamilisha tembe za malaria? 
Ndio   
LaKama ndio tafadhali toa sababu 
………………………………………………………………..………………………………… 
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Appendix 2.3: Patient care structured interview form (Dholuo) 
2B NONRO MAR RIT JATUO 
MBALARIANY MAR WESTAN CAPE 
Sikund Ajuoke mag Kor Gweng,’ 
Sanduk Mar Posta, Private Bag X 17, Bellville 7535,  
AFRIKA MAR MILAMBO. 
Sime: +27 21-9592809, Fax: 27 21-9592872 
 
Divison………………………………. 
Jatim Nonro…………………….. 
Gweng’………………......................   Tarik…………………………………….. 
Kar Thieth……………………….. 
 
Nyng(E yo 
machwok)…………….Tarik…………….Dichwo/Dhako…………Higa…………….Ratil……
……… 
Japim Yien………………. Jachiw Yien………………  
 
1.Yie inyisa nying yedhe ma daktari (Laktar/ajuoga) osango ne nyathini kawuono? 
 
1……………………….. 
2……………………….. 
3………………………. 
4………………………. 
2. Be ne omiyi yedhe duto ma ne idwaro? 
 
Yien 1…………. Eee/Ooyo/Akia 
Yien 2………… Eee/Ooyo/Akia 
Yien 3…………. Eee/Ooyo/Akia 
Yien 4…………. Eee/Ooyo/Akia  
Ka ooyo to wach gima omiyo (Non gigo ma omiyo, nyalo bedo mathoth ne achiel) 
S= Onge e hosiptal; M= pesa orem; H= an go dala; W= ok wadwar; B= onyisa ni mondo adhi 
ang’iew; O=Moro amora (Chiw ler) 
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Yien 1…………………………  
Yien 2…………………………  
Yien 3………………………… 
Yien 4……………………… 
RANYISI) 
Donge de arange yedhe  duto ma ikawo ne nyathini kawuono ? 
(Som ranyisi mondo ichwo tik kaluwore gi weche ma nitie e kore) 
Yien Teko Dos Totol mag 
yath 
Nying 
Jatuo 
Nying Hosiptal Tarik 
Yien 1       
Yien 2       
Yien 3       
Yien 4       
 
5.Yie ilerna ni ere yedhe ma thiedho malaria kuom ma omiyi gi. 
Nying yath……………………… KATA ok ang’eyo………..      
 
(Ndik dwoko ma ochiw gi jarit nyathi. Ka jarit nyathi ok nyal yango yadh malaria kata ok oyange 
ma kare to nyis gi yadh malaria ma owinjore mondo gi tiek dwoko penjo ma odong’) 
 
Penjo ma odong’ gi ni kuom yath me ne omiyi ni 
 
6.  Nyathini  be ne omi yadh malaria mokwongo e hosiptand ni kawuono? 
Eee 
Ooyo 
7.  Nga’t mane omiyi yedhe be ne ong’iyo kaka nyathini mwonyo yien mokwongo? 
Eee 
Ooyo 
8. Be ne opimni kaka idhi miyo yathi yedhe ma odong’ kichopo dala/pacho? 
 
Eee 
Ooyo 
 Ka oyie to opim kaka ne onyise  
……………………………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………….. 
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…………………………………………………………………………………………………………………………………….. 
9.  Be ne onyisi gima onego itim ka nyathi ong’ogo yedhe malaria ma omiyi gi? 
 
Eee 
Ooyo 
Ka oyie to opim kaka ne onyise 
……………………………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………… 
10 Be ne opimni duong’ kata umuhimu mar tieko “dos” mar yedhe malaria ma omiyi? 
Eee 
Ooyo 
Ka oyie to opim kaka ne onyise 
………………………………………………………………………………………………………
………………………………………………………………………………………………………
… 
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Appendix 3:University of Nairobi &Kenyatta national hospital ethics review committee 
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Appendix 4: UWC ethics and review committee approval 
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Appendix 5: Bondo district ministry of health approval 
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Appendix 6 : Participant information sheet  
Appendix 6.1: Participant information sheet (English) 
 
UNIVERSITY OF THE WESTERN CAPE 
Private Bag X 17, Bellville 7535, South Africa 
Tel: +27 21-9592809, Fax: 27 21-9592872  
 
 
PROJECT TITTLE: ASSESSMENT ON PRESCRIPTION PATTERNS AND 
AVAILABILITY OF ANTI-MALARIAL DRUGS TO CHILDREN UNDER FIVE IN A 
RURAL DISTRICT IN KENYA  
 
Dear Participant 
 
What is this study about? 
This is a project being conducted by AKOKO JOY a master’s student at the School of Public 
Health at the University of the Western Cape, South Africa. 
 
I am inviting you to take part in this research project as am interested in the malaria treatment 
being provided for children under five years of age in Bondo District. The purpose of this 
research project is to identify the prescription patterns that exist in the primary health care 
facilities among the children under five in Bondo district and compare them to the national 
treatment guidelines. The research will also assess the availability of anti-malarials to these 
children.  
 
What will I be asked to do if I agree to participate? 
If you agree to participate in this study you will be asked a number of the questions about your 
understanding of malaria treatment, particularly drug administration by the research assistants 
and to provide them with your child’s prescription book that you carry home so they can extract 
specific information about your child and the anti-malarial treatment they have received. The 
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questions will take about 15 minutes and the prescription book will be returned to you as soon as 
the research assistants have finished with the necessary documentation.  
I will keep all personal information confidential.  To help protect confidentiality, neither the 
child’s name nor your name will be recorded. The results from this project will only be presented 
in an aggregated format.  
  
What are the risks of this research? 
There are no known risks associated with participating in this research project. However, social 
and psychological risks/discomforts may arise during the interviews with the caregivers. The 
researcher will ensure confidentiality of all the information provided and any recommendations 
made will be used to improve service delivery.  
What are the benefits of this research? 
This research will not benefit you or your child directly but is likely to provide useful 
information for the Bondo district community. The results from the project will indicate whether 
the malaria prescription patterns are in accordance with the national treatment guideline and the 
research will offer recommendations to improve service delivery, especially the, quality of 
patient care and  accessibility to anti-malarials to the under five children. 
 
Do I have to be in this research and may I stop participating at any time?  
Your participation in this research is completely voluntary.  You may choose not to take part at 
all or you may withdraw at anytime during the project. If you choose not to participate, the 
treatment of your child will not be affected in any way now or in the future.  
 
What if I have questions? 
This research is being conducted by Mrs. Akoko Joy, School of Public Health at the University 
of the Western Cape.  If you have any questions about the research study itself, please contact 
Mrs. Akoko Joy at the following address: 
Cell: +254 722 407559 
Email: joy.adhiambo@gmail.com 
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Should you have any questions regarding this study and your rights as a research participant or if 
you wish to report any problems you have experienced related to the study, please contact:   
Research study supervisor: Ms. Hazel Bradley. 
University of the Western Cape 
Private Bag X17, Belville 7535 
Telephone: +27219592630 Cell: +27 72 297 9932 Fax: +2721959-2872 
 
Research study local supervisor, 
Dr Onditi Kodhiambo Maurice, 
Lecturer Kenyatta University, School of health sciences 
P.O. Box 43844-00100. 
Nairobi, Kenya. 
Telephone +254 20 813460 cell +254 724468162 
 
Head of Department: Prof Uta Lehmann 
University of the Western Cape 
Private Bag X17, Belville 7535 
Telephone: +27 21959 2633  Cell: +272 82 202 3189 
 
Dean of the Faculty of Community and Health Sciences: Prof Hester Klopper 
University of the Western Cape 
Private Bag X17 
Bellville 7535 
Telephone: +27 219592809      
 
KNH/UON –ERC 
P.O.BOX 19676-00200, 20723-00200 
NAIROBI. 
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Telephone +254 20 2726300 ext 44355, +254 726300-9  
This research will be approved by both the local  ethics and review committee i.e. university of 
Nairobi and Kenyatta national  hospital ethics review committee  and the University of the 
Western Cape’s Senate Research  and Ethics Committee. 
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Appendix 6.2: Participant Information sheet (Swahili ) 
karatasi ya maelezo ya washiriki 
 
CHUO KIKUU CHA CAPE YA MAGHARIBI                                
                         Private Bag X 17, Bellville 7535, Afrika Kusini 
                           Tel:  +27 21-9592809, Fax: 27 21-9592872 
 
MRADI WA UTAFITI: TATHMINI YA MIFUMO YA DAWA NA 
UPATIKANAJI WA DAWA ZA KUPAMBANA NA MALARIA KWA WATOTO CHINI 
YA MIAKA MITANO KATIKA KIJIJI KIMOJA NCHINI KENYA 
Ndugu Mshiriki  
Je, utafiti huu ni juu ya nini? 
Huu ni mradi unaofanywa na Bi. AKOKO JOY mwanafunzi wa shahada ya masters, Shule ya 
Afya ya Umma katika Chuo Kikuu cha Cape ya Magharibi, Afrika Kusini.  
Tunakukaribisha kushiriki katika mradi huu wa utafiti, tuna nia ya kufanya utafiti juu ya 
matibabu ya malaria inayotolewa kwa watoto chini ya miaka mitano katika Wilaya 
ya Bondo. Madhumuni ya mradi huu ni kutambua ruwaza ambazo zipo katika vituo vya afya vya 
kimsingi vinavyo toa huduma ya matibabu ya malaria miongoni mwa watoto chini ya miaka 
mitano katika wilaya ya Bondo na kuyalinganisha na miongozo ya kitaifa ya 
matibabu. Utafiti pia unanuiya kutathmini upatikanaji wa madawa ya kupambana na malaria kwa 
watoto hawa. 
Nitaulizwa maswali gani kama nitakubali kushiriki? 
Kama utakubali kushiriki katika utafiti huu utaulizwa maswali kadhaa kuhusu uelewevu wako 
wa tiba ya malaria, upeanaji wa madawa ya malaria hasa na watafiti wasaidizi 
nakuwapatia kitabu cha matibabu cha mtoto wako ambacho wewe hubeba kwenda nyumbani ili 
waweze kudondoa taarifa maalum kuhusu mtoto wako na tiba ambayo ameweza kupata dhidi ya 
malaria. Maswali yatachukua muda wa dakika 15 na kitabu kitarejeshwa kwako pende watafiti 
wasaidizi watakapo kamilisha utafiti wa nyaraka muhimu. 
Tutaweka taarifa zote za kibinafsi siri. Kusaidia kulinda siri, jina lako wala la mtoto halitakuwa 
kwenye kumbukumbu. Matokeo kutokana namradi huu utawasilishwa kwa njia ya siri. 
Je, utafiti huu una hatari gani? 
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Hakuna hatari inayojulikana kuhusishwa na kushiriki katika mradi huu wa utafiti 
 Utafiti huu una manufaa gani? 
Utafiti huu haitakuwa na faida wa moja kwa moja kwako au mtoto wako lakini ni uwezekano 
wa kutoa taarifa muhimu kwa ajili ya jamii ya wilaya ya Bondo. Matokeo kutoka mradi huu 
yataonyesha kama dawa za malaria yanatolewa kwa mujibu wa mwongozo wa kitaifa,  na utafiti 
utatoa mapendekezo ya kuboresha utoaji wa huduma, hasa utoaji wa huduma bora kwa 
mgonjwa na upatikanaji wa dawa za kupambana na malaria kwa watoto chini ya miaka mitano. 
Je, lazima niwe katika utafiti huu na naweza omba kuacha kushiriki katika utafiti huu 
wakati wowote? 
Ushiriki wako katika utafiti huu ni wa hiari kabisa. Unaweza kuchagua kutoshiriki kabisa au 
unaweza kuondoka wakati wowote katikati ya mradi. Kama utachagua kutoshiriki, matibabu 
ya mtoto wako hayataathirika kwa njia yoyote sasa au katika siku zijazo. 
Na Kama nina maswali? 
Utafiti huu unafanywa na Bi Akoko Joy, mwanafunzi wa Shule ya Afya ya Umma katika Chuo 
Kikuu cha Cape Magharibi. Kama unamaswali kuhusu utafiti wenyewe, tafadhali wasiliana 
na Bi Akoko Joy kwa anwani ifuatayo:  
Cell: +254 722 407559       
Email: joy.adhiambo @ gmail.com 
Kama una maswali yoyote kuhusu utafiti huu na haki yako kama mshiriki au kama unataka kutoa 
taarifa kuhusu tatizo lolote kuhusiana na utafiti huu, tafadhali wasiliana na: 
 
Msimamizi mkuu wa utafiti: Bi Hazel Bradley. 
Chuo Kikuu cha Cape ya Magharibi 
Private Bag X17, Belville 7535 
Simu: +27219592630 Cell: +27 72 297 9932 Fax: +2721959-2872 
Mkuu wa Idara: Prof Uta Lehmann 
Chuo Kikuu cha Cape ya Magharibi 
Private Bag X17, Belville 7535 
Simu: +27 21959 2633       Cell: +272 82 202 3189 
Mkuu wa Kitivo cha Sayansi ya Afya ya Jamii: Prof HesterKlopper 
Chuo Kikuu cha Cape ya Magharibi 
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Private Bag X17 Bellville 7535 
Simu: +27 219592809       
Utafiti huu utaidhinishwa na kamati ya seneti ya utafiti na maadili cha Chuo Kikuu 
cha Cape Magharibi.  
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Appendix 6.3: Participant Information sheet (Dholuo) 
form mar yie golo paro e nonro 
MBALARIANY MAR WESTAN CAPE 
Sikund Ajuoke mag Kor Gweng,’ 
Sanduk Mar Posta, Private Bag X 17, Bellville 7535,  
AFRIKA MAR MILAMBO. 
Sime: +27 21-9592809, Fax: 27 21-9592872  
 
THUON WACH: YANGO TIE (YUDRUOK) KOD KAKA ICHIWO YEDHE MAG 
MALARIA NE NYITHINDO MA BWO HIGNI ABICH E GWENGE MA KENYA. 
 
Ne Jakanyono, 
Nonro ni itimo gi AKOKO JOY ma en japunjre mar rang’iny mar “masters” e sikul mar ajuok 
kor gwenge e mbalariany mar Western Cape man nitie e piny ma Africa ma Milambo. 
 
Warwaki ni mondo igol pachi e nonro ni nikech en hero wa ni mondo wang’e kaka ithiedho 
malaria kuom nyithindo ma ni e bwo higni abich e district mar Bondo. Nonro ni dwaro yango 
kaka ichiwo yedhe ne nythindo ma bwo higni abich e hosipatande ma Bondo mondo wapim gi 
kaka sirkal dwaro. Nonro ni be biro fwenyo tie(yudruok) mar yedhe gi ne nythindo ma e bwo 
higni abich. 
 
En ang’o ma ibiro penja ka ayie golo pacha? 
Ka iyie to ibiro penji penjo moko ma bwora kaluwore gi winjoni e thieth mar malaria, ahinya to 
e chiwo yedhe, toke to ibiro kwayi bug hospital mar nyathini mondo yud tiend weche e thieth 
mar malaria ma osechiw ne nyathini. Penjo biro kawo dakika apar kod abich tok ma ibiro dwok 
ni bug nyathini mar hospital. Weche duto ma ibiro chiwo ok bi nyis nga’to ang’ata kendo kata 
nying nyathini ok bi ndiki kamoro amora.  
  
Rach moro dibedie e golo pacha? 
Onge rach moro amora manyalo wuok e paro ma ibiro golo. Pachi biro mana kelo ber e konyo 
thieth mar malaria ne nyithindo ma bwo higni abich. 
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Ber mage ma nonro ni biro kelo? 
Ber ma achiel ka achiel ne in kata nyathini to onge. Kata kamano, paro ma ibiro chiwo biro 
konyo aluora mar Bondo nikech fweny ma nonro ni dhi golo biro yawo wang’ kuom kaka thieth 
mar malaria chalo e aluora mar Bondo ma biro yango ka thieth ma ichiwo oluwore gi kaka sirkal 
(piny owach) dwaro. Ibiro fweny bende kuonde ma inyalo jiw mondo chiw thieth makare mar 
malaria ne nythindo ma pok okalo higni abich. 
 
Ochuno ni nyaka abedi jakanyono e nonro ni to be an kod thwolo mar loko pacha kapok 
nonro ni orumo? 
Paro duto ma ibiro golo en kuom yie mari. Inyalo dagi bedo jakanyono, kata inyalo wuok e 
nonro nus. Tamruok ni ok bi mono thiedh nyathini kuom seche gi to kata mana bang’e. 
 
To ka an gi penjo? 
Nikech nonro ni itimo kod mikai AKOKO JOY ma mbalariany mar Westan Cape, penjo duto 
inyalo or ne ka okalo e  ong’we yamo kata it oboke mar mbui ma piny ni: 
Sime: +254 722 407559 
Email: joy.adhiambo@gmail.com 
 
Kuom penjo duto ma oluwore gi ratiro magi e nonro ni kata chandruok moro amora ma diwuog e 
nonro ni to iyie itudri gi: 
Nyapara Mar Nonro: Ms. Hazel Bradley. 
Mabalariany Mar Westan Cape, 
Private Bag X17, Belville 7535 
Sime: +27219592630 Cell: +27 72 297 9932 Fax: +2721959-2872 
 
Jatend Migao: Prof Uta Lehmann, 
Mbalariany Mar Westan Cape, 
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Private Bag X17, Belville 7535 
Sime: +27 21959 2633  Cell: +272 82 202 3189 
 
 
Jatend Migap ajuoke mag kor gwenge: Prof Hester Klopper 
Mabalariany Mar Westan Cape, 
Private Bag X17 
Bellville 7535 
Sime: +27 219592809       
 
Nonro ni ibiro go kogno gi Telo mochung’ ne ratiro mar Mbalariany ma Westan Cape.  
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Appendix 7: Consent form  
Appendix 7.1: Consent form (English) 
 
 UNIVERSITY OF THE WESTERN CAPE 
        School of Public Health 
 
Private Bag X17 ● BELLVILLE ● 7535 ● South Africa 
               Tel: 021- 959 2809, Fax: 021- 959 2872 
 
 
Title of Research Project: ASSESSSMENT ON PRESCRIPTION PATTERNS AND 
AVAILABILIT OF ANTI-MALARIA DRUGS TO CHILDREN UNDER FIVE IN A 
RURAL DISTRICT IN KENYA 
 
The study has been described to me in language that I understand and I freely and voluntarily 
agree to participate. My questions about the study have been answered. I understand that my 
identity will not be disclosed and that I may withdraw from the study without giving a reason at 
any time and this will not negatively affect me in any way.   
 
Participant’s name…....................................................................... 
Participant’s signature……………………………….                                   
Date……………………… 
 
Should you have any questions regarding this study or wish to report any problems you have 
experienced related to the study, please contact the study Supervisor 
Research study supervisors’ Name: Ms. Hazel Bradley. 
University of the Western Cape 
Private Bag X17, Belville 7535 
Telephone: +27219592630 Cell: +27 72 297 9932 Fax: +2721959-2872 
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Research study local supervisor, 
Dr Onditi Kodhiambo Maurice, 
Lecturer Kenyatta University, School of health sciences 
P.O.Box 43844-00100. 
Nairobi, Kenya. 
Telephone +254 20 813460 cell +254 724468162 
 
Head of Department: Prof Uta Lehmann 
University of the Western Cape 
Private Bag X17, Belville 7535 
Telephone: +2721 959 2633  Cell: +272 82 202 3189 
 
Dean of the Faculty of Community and Health Sciences: Prof Hester Klopper 
University of the Western Cape 
Private Bag X17 
Bellville 7535 
Telephone: +2721959 2809   
 
 KNH/UON –ERC 
P.O.BOX 19676-00200, 20723-00200 
NAIROBI. 
Telephone +254 20 2726300 ext 44355,  +254 726300-9  
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Appendix 7.2: Consent form (Kiswahili) 
 Fomu ya idhini 
 
CHUO KIKUU CHA CAPE YA MAGHARIBI 
               Shule ya Afya ya Umma 
Private Bag X17 ● Bellville 7535 ● Afrika Kusini 
                       Tel: 021-959 2809, Fax: 021-959 2872 
MRADI WA UTAFITI: TATHMINI YA MFUMO WA DAWA NA UPATIKANAJI WA 
DAWA ZA KUPAMBANA NA MALARIA KWA WATOTO CHINI YA MIAKA 
MITANO KATIKA KIJIJI KIMOJA NCHINI KENYA 
Utafiti umeelezwa katika lugha ambayo naelewa, ninashiriki kwa huru na kwa hiari. Maswali 
yangu kuhusu utafiti huu yamejibiwa. Naelewa kwamba 
utambulisho wangu hautafunuliwa na kwamba naweza kuondoka kwenye utafiti huu bila ya 
kutoa sababu wakati wowote na hii haitaniathiri kwa njia yoyote. 
Jina la mshiriki.................................................. ........................ 
Sahihi ya mshiriki..................................... 
Tarehe................... 
Kama, una swali lolote kuhusu utafiti huu au unataka kuripoti matatizo yoyote ambayo 
umekumbana nayo katika utafiti huu, tafadhali wasiliana na Msimamizi wa utafiti 
Jina la mtafiti msimamizi: Bi Hazel Bradley. 
Chuo Kikuu cha Cape ya Magharibi 
Private Bag X17, Belville 7535 
Simu: +27219592630       Cell: +27 72 297 9932       Fax: +2721959-2872 
 Mkuu wa Idara: Prof Uta Lehmann 
 Chuo Kikuu cha Cape ya Magharibi 
 Private Bag X17, Belville 7535 
 Simu: +2721 959 2633    Cell: +272 82 202 3189 
 
Mkuu wa Kitivo cha Sayansi ya Afya ya Jamii: Prof HesterKlopper 
Chuo Kikuu cha Cape ya Magharibi 
Private Bag X17 
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Bellville 7535 
Simu: +2721959 2809       
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Appendix 7.3: Consent form (Dholuo) 
 
MBALARIANY MAR WESTAN CAPE 
Sikund Ajuoke mag Kor Gweng,’ 
Sanduk Mar Posta, Private Bag X 17, Bellville 7535,  
AFRIKA MAR MILAMBO. 
Sime: +27 21-9592809, Fax: 27 21-9592872  
 
FORM MAR YIE GOLO PARO E NONRO 
THUON WACH: YANGO TIE (YUDRUOK) KOD KAKA ICHIWO YEDHE MAG 
MALARIA NE NYITHINDO MA BWO HIGNI ABICH E GWENGE MA KENYA. 
 
Ne Jakanyono, 
Nonro ni itimo gi AKOKO JOY ma en japunjre mar rang’iny mar “masters” e sikul mar ajuok 
kor gwenge e mbalariany mar Western Cape man nitie e piny ma Africa ma Milambo. 
 
Warwaki ni mondo igol pachi e nonro ni nikech en hero wa ni mondo wang’e kaka ithiedho 
malaria kuom nyithindo ma ni e bwo higni abich e district mar Bondo. Nonro ni dwaro yango 
kaka ichiwo yedhe ne nythindo ma bwo higni abich e hosipatande ma Bondo mondo wapim gi 
kaka sirkal dwaro. Nonro ni be biro fwenyo tie(yudruok) mar yedhe gi ne nythindo ma e bwo 
higni abich. 
 
En ang’o ma ibiro penja ka ayie golo pacha? 
Ka iyie to ibiro penji penjo moko ma bwora kaluwore gi winjoni e thieth mar malaria, ahinya to 
e chiwo yedhe, toke to ibiro kwayi bug hospital mar nyathini mondo yud tiend weche e thieth 
mar malaria ma osechiw ne nyathini. Penjo biro kawo dakika apar kod abich tok ma ibiro dwok 
ni bug nyathini mar hospital. Weche duto ma ibiro chiwo ok bi nyis nga’to ang’ata kendo kata 
nying nyathini ok bi ndiki kamoro amora.  
  
Rach moro dibedie e golo pacha? 
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Onge rach moro amora manyalo wuok e paro ma ibiro golo. Pachi biro mana kelo ber e konyo 
thieth mar malaria ne nyithindo ma bwo higni abich. 
 
 
 
Ber mage ma nonro ni biro kelo? 
Ber ma achiel ka achiel ne in kata nyathini to onge. Kata kamano, paro ma ibiro chiwo biro 
konyo aluora mar Bondo nikech fweny ma nonro ni dhi golo biro yawo wang’ kuom kaka thieth 
mar malaria chalo e aluora mar Bondo ma biro yango ka thieth ma ichiwo oluwore gi kaka sirkal 
(piny owach) dwaro. Ibiro fweny bende kuonde ma inyalo jiw mondo chiw thieth makare mar 
malaria ne nythindo ma pok okalo higni abich. 
 
Ochuno ni nyaka abedi jakanyono e nonro ni to be an kod thwolo mar loko pacha kapok 
nonro ni orumo? 
Paro duto ma ibiro golo en kuom yie mari. Inyalo dagi bedo jakanyono, kata inyalo wuok e 
nonro nus. Tamruok ni ok bi mono thiedh nyathini kuom seche gi to kata mana bang’e. 
 
To ka an gi penjo? 
Nikech nonro ni itimo kod mikai AKOKO JOY ma mbalariany mar Westan Cape, penjo duto 
inyalo or ne ka okalo e  ong’we yamo kata it oboke mar mbui ma piny ni: 
Sime: +254 722 407559 
Email: joy.adhiambo@gmail.com 
 
Kuom penjo duto ma oluwore gi ratiro magi e nonro ni kata chandruok moro amora ma diwuog e 
nonro ni to iyie itudri gi: 
Nyapara Mar Nonro: Ms. Hazel Bradley. 
Mabalariany Mar Westan Cape, 
Private Bag X17, Belville 7535 
Sime: +27219592630 Cell: +27 72 297 9932 Fax: +2721959-2872 
 
 
 
 
 
80 | P a g e  
 
Jatend Migao: Prof Uta Lehmann, 
Mbalariany Mar Westan Cape, 
Private Bag X17, Belville 7535 
Sime: +27 21959 2633  Cell: +272 82 202 3189 
 
 
Jatend Migap ajuoke mag kor gwenge: Prof Hester Klopper 
Mabalariany Mar Westan Cape, 
Private Bag X17 
Bellville 7535 
Sime: +27 219592809       
 
Nonro ni ibiro go kogno gi Telo mochung’ ne ratiro mar Mbalariany ma Westan Cape.  
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Appendix 8: A sample of blister pack for 5kg and less than 14kg 
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Appendix 9: A sample of an al blister pack for weight 15kg and less than 25kg 
 
 
 
 
 
 
 
 
 
 
